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Abstract 
Previous studies showed haploinsufficiency of RAI1 is the main cause of Smith-Magenis 
syndrome (SMS).  SMS is a developmental neurobehavioral syndrome characterized by 
intellectual disability, congenital anomalies, obesity, neurobehavioral abnormalities, and 
disrupted circadian sleep-wake pattern.  SMS is caused by deletion or mutation of chromosomal 
region 17p11.2 that includes RAI1.  Studies in the Elsea lab have shown that RAI1 is a dosage-
sensitive gene.  Haploinsufficiency of RAI1 leads to dysregulation of CLOCK, NR1D2, POMC, 
and BDNF, which are responsible for circadian rhythm, metabolism, and cognitive development.  
Based on the data from Elsea’s recent study on zebrafish, rai1 gene expression in zebrafish is 
regulated by retinoic acid.  Treatment with retinoic acid increases the expression of rai1.  In this 
study, we focused on the effect of retinoic acid on human RAI1 expression.  We found the 
expression of RAI1 was enhanced by the treatment with retinoic acid. The different 
concentrations of the retinoic acid affect the levels of increase in expression, but we found little 
evidence that RAI1 expression was affected by the length of treatment time.  In this study, we 
were unable to find consistency in the pattern of changes in the expression level in respect to the 
different treatment concentrations.  We identified nine strong retinoic acid response element 
(RARE) candidate sites upstream of the start codon in human RAI1.  Since there are possible 
RARE sites present in the upstream sequence of RAI1, it is more likely that RAI1 is regulated by 
retinoic acid.  However, further experimental evidence will be needed to confirm those sites 
selected in silico are able to bind RAR/RXR heterodimers, to prove the selected sites are real 
RARE sites and were not identified by chance. 
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Introduction 
Previous studies show that haploinsufficiency of RAI1 (retinoic acid induced 1) is the 
cause of Smith-Magenis syndrome (SMS) (3).  SMS is a developmental neurobehavioral 
syndrome characterized by intellectual disability, congenital anomalies, obesity, neurobehavioral 
abnormalities, and disrupted circadian sleep-wake pattern (3).  SMS is caused by deletion or 
mutation of chromosomal region 17p11.2 that includes RAI1.  Studies in the Elsea lab have 
shown that RAI1 is a dosage-sensitive gene (3).  Haploinsufficiency of RAI1 leads to 
dysregulation of CLOCK (circadian locomotor output cycles kaput), NR1D2 (nuclear receptor 
subfamily 1, group D, member 2), POMC (proopiomelanocortin), and BDNF (brain-derived 
neurotrophic factor), which are responsible for circadian rhythm, metabolism, and cognitive 
development (4, 5).
 
On the other hand, duplication of the same region, 17p11.2, results in the reciprocal 
syndrome, Potocki-Lupski syndrome (PTLS) (8).  PTLS is a microduplication syndrome 
characterized by intellectual disability, behavioral abnormalities, sleep apnea, cardiovascular 
anomalies, hypermetropia, autistic spectrum disorders, mild facial dimorphism, infantile 
hypotonia, and failure to thrive (8).  Data show that-over expression of RAI1 causes most of the 
problems that lead to PTLS. 
The gene RAI1 is the critical gene that causes SMS.  RAI1 is a dosage sensitive gene, 
acting as a transcriptional regulator.  Based on the data from Elsea’s recent study on zebrafish, 
rai1 gene expression in zebrafish is regulated by retinoic acid (Elsea et al. unpublished data).  
Treatment with retinoic acid increases the expression of rai1.  Whether retinoic acid regulates 
human RAI1 is unknown; however, the regulation of a wide variety of essential biological 
processes by retinoic acid have been studied.  For example, vertebrate embryonic morphogenesis, 
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organogenesis, cell growth arrest, differentiation and apoptosis, and homeostasis are all regulated 
by retinoic acids (22).
  
 
 Following a recent study on zebrafish in the Elsea lab to show that rai1 in zebrafish is 
regulated by retinoic acid, we move on to the human RAI1 and try to prove that the human RAI1 
is also regulated by retinoic acid.  In this study, we want to show that RAI1 expression will be 
enhanced by the treatment of retinoic acid.  We also want to find the treatment that uses the least 
amount of retinoic acid and the shortest treatment time without damaging the cells to increase the 
expression of RAI1 by about 1.5 fold, so it will not lead to PTLS.   
Based on published studies, retinoic acid regulated genes have specific RARE DNA 
sequences in the promoter region of retinoid target genes.  Those sites usually have a relaxed 
sequence of ‘(a/g)g(g/t)(g/t)(g/c)a’ separated by five (DR5) or one (DR1) or two (DR2) 
nucleotides (22).  These sites are as likely to be found within the coding strand as the non-coding 
strand.  About 86% of those sites are in upstream locations (22).  Retinoic acid receptors will 
bind those sites in order to regulate gene expression.   
The RARs and RXRs are the two families of retinoic acid receptors.  Three RAR 
subtypes, e.g., RARα, RARβ, RARγ, originate from three distinct genes.  RARα1 / RARα2 and 
RARγ1 / RARγ2 are the two isoforms for RARα and RARγ (23). RARβ1 - RARβ4 are the four 
isoforms for RARβ (23).  The RAR receptors will bind with any of the three RXRs to form 
heterodimers.  If the retinoic acid target gene has a RARE sequence of DR2 and DR5, RXRs will 
occupy the 5’ element, and RARs will occupy the 3’ element to form a ‘5’-RXR-RAR-3’’ 
heterodimer.  The RXR-RAR heterodimer is reversed in the DR1 sequence to form a ‘5’-RAR-
RXR-3’’ heterodimer (23).  
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In the second part of this study, we start our search of RAI1 RARE sites utilizing the 
relaxed binding site sequence, ‘(a/g)g(g/t)(g/t)(g/c)a’, and online open sources.  The search is 
then carried out with customized Perl programs, findSeq, which is a sequence-pattern-match 
based search program, and findMotif, which is a motif finding search.  The results will be 
compared and analyzed in order to predict the possible RARE site(s). Because the short length, 
poor conservation, and low information densty, it is difficult to identify RARE sites.  
Nevertheless, the preferred approaches were used in previous studies.  A similar study has been 
done by Laperriere’s team.  They found 17 DR2 RARE sites genome wide within the ENCODE 
ChIP-on-chip RARα binding regions, and confirmed 16 other DR2 RARE sites, including 3 
found in the promoter region of RAI1,  by ChIP assay experiments (26). 
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Literature Review 
Smith-Magenis syndrome (SMS) 
SMS, first described by Ann C. M. Smith and R. Ellen Magenis in 1986 (1) and affecting 
about 1: 25,000 births (2), is a developmental neurobehavioral syndrome characterized by 
distinctive physical features that progress with age, developmental delay, cognitive impairment, 
and neurobehavioral abnormalities (3, 4).  The facial abnormalities of SMS patients include a 
broad square shaped face, brachycephaly, midface hypoplasia, micrognathia that progress to 
relative prognathism with age, upslanting palpebral fissures, deep set eyes, short full tipped nose, 
tented upper lip, and downturned corners of the mouth (Figure 1) (4).  Infants with SMS have 
feeding difficulties, failure to thrive, hypotonia, hyporeflexia, and abnormal sleep patterns, such 
as prolonged napping or the need to be awakened for feedings (4).  The majority of SMS 
individuals also have self-injurious behaviors, such as self-hitting, self-biting, and/or skin 
picking, inserting foreign objects into body orifices, and pulling out fingernails and/or toenails. 
These behaviors are usually not recognized until the individuals are 18 months old, and these 
individuals continue to change until adulthood (4).  
  
    
 
5 
 
 
 
Figure 1 Facial abnormalities of SMS patients during different stages of life 
The left panel shows infants with SMS. Both present with brachycephaly, broad forehead, 
upslanting palpebral fissures, short upturned nose, and down-turned “tent” shaped upper lip. The 
middle panel shows SMS patients at early school age presenting with broad forehead, deep-set 
eyes, and midface retrusion.  The right panel shows adolescent females with SMS.  The left 
frames show a SMS female with a mutation in RAI1 mutation, and the right frames show a SMS 
female with a deletion of 17p11.2.  Both patients present with short philtrum and down-turned 
upper lip. 
Source: Smith ACM, Boyd KE, Elsea SH, et al, 2001 
SMS is caused by the deletion or mutation of chromosomal region 17p11.2 that includes 
the gene, RAI1.  RAI1 is a dosage-sensitive gene that acts as a transcriptional regulator (5).  It is 
the critical gene that causes SMS, and is responsible for the majority of the characteristics of 
SMS (5, 6).  Haploinsufficiency of RAI1 leads to dysregulation of downstream genes, such as 
CLOCK and BDNF, which are responsible for circadian rhythm, metabolism, and cognitive 
development (5, 7).  ChIP-chip and luciferase data suggest the transcriptional activity of CLOCK 
is enhanced when RAI1 binds to the first intron of CLOCK directly or in a complex (5). The data 
supported that RAI1 is a positive regulator of CLOCK and an important part of the circadian loop 
of transcription (5).  Therefore, heterozygous mutations or deletions of RAI1 lead to a disrupted 
circadian rhythm that causes the abnormal sleep-wake cycle in SMS patients (5).  A similar study 
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done by Burns et al. (2010) showed that RAI1 regulates the transcription of BDNF though an 
intron 1 enhancer element (7).  The overexpression of RAI1 results in increased luciferase 
activity, which indicates RAI1 is a positive regulator of BDNF (7).   Haploinsufficiency of RAI1 
leads to reduced BDNF expression, and resulting in hyperphagia, obesity and altered fat 
distribution in both mice and humans (7).  Even though the genotype and phenotype analyses 
done by Girirajan et al. (2006) showed that 21 of 30 SMS features are the results of 
haploinsufficiency of RAI1, other genes within 17p11.2 also contribute to the various features 
and overall severity of SMS (6).  
 
Cardiac anomalies, speech and motor delay, hypotonia, short 
stature, and hearing loss are associated with 17p11.2 deletions rather than RAI1 mutations (6).   
Potocki–Lupski syndrome (PTLS) 
PTLS is the reciprocal disease of SMS, also known as dup (17) p11.2p11.2 syndrome or 
trisomy 17p11.2 (8).  PTLS is a microduplication syndrome involving the short arm of 
chromosome 17, the same region, 17p11.2, which is critical to SMS (8).  Most PTLS patients 
present with sporadic microduplication of 17p11.2 and share a common 3.7 Mb duplication 
within 17p11.2 that includes RAI1.   An analysis of variants led to the identification of RAI1 and 
17 other genes within the same critical region affected in SMS (8).   
Both PTLS and SMS are characterized by congenital abnormalities, intellectual disability, 
and autism spectrum disorder (8).  However, individuals with PTLS present with milder defects 
than SMS.  Other characteristics of PTLS include behavioral abnormalities, language disorders, 
sleep apnea, structural and conduction cardiovascular anomalies, hypermetropia, mild facial 
dysmorphism, infantile hypotonia, low muscle tone, and failure to thrive (8). 
There have been no reported cases involving duplication of only a single gene.  However, 
in Lee’s study, RAI1 expression was found in all tissues examined; higher RAI1 expression was 
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found in both heart and brain (8).  Based on previous studies using mouse models, RAI1 was 
suggested to be responsible for most of the features present in PTLS patients, including low body 
weight, increased anxiety, and learning and memory deficits (9).   
RAI1  
Rai1 (GT1) was first identified in mouse pluripotent embryonic carcinoma cells 
(P19) treated with retinoic acid by Imai’s team (35). Rai1 was differentially cloned by enhanced 
expression associated with RA treatment (35).  The structure of RAI1 gene consists of six exons 
(Figure 2).  All reported mutations in SMS patients are located in exon III, which is the first 
coding exon of RAI1, and it encompasses of over 95% of the coding sequence. The protein 
structure of RAI1 contains the polyglutamine and polyserine tracts, a C-terminal plant 
homeodomain, and the bipartite nuclear localization signals (2).  The polyserine tracks are 
similar to the motifs found in Drosophila hairless genes (2). These motifs have been shown to be 
involved in development of the nervous system and transcription of genes (36, 37).  A recent 
study has showed that the bipartite nuclear localization signals is located in the novel 
nucleosome binding region of and has the ability to bind the nucleosome core and histones (38, 
39). The C-terminal plant homodomian also interacts with nucleosomes, and is dependent on the 
histone tails (38, 39). It is a dosage sensitive gene that acts as transcriptional regulator (5).   
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Figure 2 Structure of human RAI1 
The top panel shows the genomic structure of RAI1. The boxes represent the exons of RAI1.  The 
blank regions are the non-coding regions, and the yellow ones are the coding regions. The 
bottom panel shows the protein structure of RAI1. It includes a polyglutamine (Poly-Q), 
polyserine (Poly-S), a bipartite nuclear localization signal (NLS), and C-terminal plant 
homeodomain (PHD). 
Source: Elsea and Girirajan 2008 
 
The gene RAI1 is the critical gene that is responsible for the majority of the 
characteristics of SMS and PTLS (5-8, 10).  Haploinsufficiency of RAI1 leads to dysregulation of 
CLOCK and NR1D2, which results in disrupted circadian rhythm that causes the abnormal sleep-
wake cycle.  Also the dysregulated POMC and BDNF due to haploinsufficiency of RAI1 is likely 
contributing to the abnormal metabolism and impaired satiety and abnormal cognitive 
development and function in SMS patients (7).  On the other hand, overexpression of RAI1 
results in majority of the features presented in PTLS patients (8-10).  In Walz’s study, 
Dp(11)17/+ is the mouse model for dup(17)(p11.2p11.2), Rai1
+/–
 mice carries a null mutation 
in Rai1, and Dp(11)17/Rai1
– 
mice carries hemizygous duplication of 3 Mb containing Rai1 along 
with 18 other genes on one chromosome and  a null allele of Rai1 on the other chromosome (2 
copies of the Rai1 and  3 copies of the other 18 genes that are involved in PTLS).  Walz found 
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the Dp(11)17/Rai1
– 
mice showed body weight similar to wildtype mice but significantly different 
from the Dp(11)17/+ and Rai1
+/–
 mice. This indicates that the duplication of Rai1 is responsible 
for the reduced body weight in PTLS mice (10). In the same study by Walz et al., showed 
Dp(11)17/Rai1
–
 mice displayed similar levels of anxiety-related behaviors; however, the 
Dp(11)17/+ exihibited increased anxiety-related behaviors, which indicates that duplication of 
Rai1 is responsible for the high level of anxiety in PTLS mice (10).  A similar experiment 
showed the lack of learning and memory ability is also directly related to Rai1 copy number (10). 
Retinoic Acid  
Retinoic acid is a type of retinoid, which refers to the natural dietary vitamin A (retinol) 
metabolites and active synthetic analogs (11).  The all-trans-retinoic acid is the most important 
endogenous retinoid (11).  It was co-developed as an acne treatment by James Fulton and Albert 
Kligman in 1969 (12).  The all-trans-retinoic acid is also used in the treatment of acute 
promyelocytic leukemia with other drugs (13, 14).   
High-dose retinoic acid is harmful during pregnancies.  Studies have shown that women 
who consumed more than 10,000 IU (3 mg) of vitamin A per day were at risk to have infants 
with congenital abnormalities of structures with a neural crest cell contribution, conotruncal 
heart defects, cleft lip or cleft palate, and ear malformations (15).  Based on Fernhoff and 
Lammer’s study, 95 out of 154 investigated human pregnancies with fetal exposure to retinoic 
acid were elective abortions, 12 spontaneous abortions, and 21 malformed infants (16).    
Retinoic acid receptors and retinoic acid responsive element (RARE)  
Retinoic acid molecules are not able to bind to the target genes directly.  Instead, they 
regulate genes by binding to retinoic acid receptors that function as transcription factors.  The 
RARs and the RXRs are the two families of retinoic acid receptors, each of which has three 
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subtypes, α, β, and γ (11).  RARα (NR1B1) was first identified by both Pierre Chambon’s and 
Ron Evans’ group in 1987 (17).  RARβ (NR1B2) was first identified in a hepatocellular 
carcinoma where it flanks a hepatitis B virus integration site by de Thé H et al. (18).  RARγ 
(NR1B3) was the third human RAR characterized by Chambon’s group (19).  RARα (NR1B1), 
RARβ (NR1B2), and RARγ (NR1B3) are originated from three distinct genes (17-21).  
 
Figure 3 Basic structure of the retinoic acid receptors 
The isoforms differ in the N-terminal region A, which is indicated as the blue region in the 
illustration.  Region C contains 2 zinc-binding motifs that correspond to the core of the DNA 
binding domain (DBD).  It is highly conserved among the three RAR and RXR types.  The 
ligand binding domain (LBD) is located at region E which is also highly conserved among the 
three types of both RAR and RXR.  Region F in RAR has no counterpart in RXR. 
Source:  P.P. Albrecht and J.P. Vanden Heuvel, 2012 
 
The RARs and RXRs have similar structure that can be divided into 6 regions (A - F) 
(11).  The 2 zinc-binding motifs that located in region C correspond to the DNA binding domain 
(DBD).  It confers specificity and recognizes the cognate response elements.  This region is 
highly conserved between the three RAR types (94-97%) and the three RXR types (91-97%) (11). 
Region E, which contains the ligand binding domain (LBD), is also highly conserved between 
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the three RAR types (84-90%) and the three RXR types (88-95%) (11). The function of region F 
is unknown, and it’s not conserved among the three RAR types.  There is no region F in RXRs. 
The N-terminal of region A domain differentiate the isoforms of each RAR and RXR types.  
These isoforms arise from the different usages of two promoters and alternative splicing (17).  
There are two isoforms for RARα and RARγ (RARα1 / RARα2 and RARγ1 / RARγ2), and four 
isoforms for RARβ (RARβ1 - RARβ4).  The RARs will bind with the RXRs, which also have 
three subtypes (RXRα (NR2B1), RXRβ (NR2B2), and RXRγ (NR2B3)), to form heterodimers 
and then bind to the target genes.  Two different isoforms for each of the three RXR subtypes 
differ primarily at the amino terminus (RXRα1 / RXRα2, RXRβ1 / RXRβ2, RXRγ1 / RXRγ2) 
(11). 
The targeted retinoic acid-regulated genes have specific RARE sequences in the promoter 
region.  Those sites usually have a consensus sequence of ‘(a/g)g(g/t)(g/t)(g/c)a’ separated by 
five (DR5), one (DR1), or two (DR2) nucleotides (22).  These sites are as likely to be found on 
the coding strand as on the non-coding strand, and about 86% of those sites are in upstream 
locations (22). Based on Balmer and Blomhoff’s analyzed data, 92% of the RARE sequences 
have direct-repeat symmetry (22). However, other orientations, such as palindromic or inverted 
palindrome, and/or wider spacing have also been identified as RAREs (22).  The RAR-RXR 
heterodimers will bind to the RARE sequences in order to regulate the targeted gene expression 
(11, 22).  If the retinoic acid targeted gene has a RARE sequence of DR2 and DR5, RXRs will 
occupy the 5’ element, and RARs occupy the 3’ in an orientation of ‘5’-RXR-RAR-3’’.  It is 
reversed in the DR1 sequence and will form a ‘5’-RAR-RXR-3’’ heterodimer (22).  
Even though how retinoic acid regulates RAI1 is unknown, studies on the regulation of a 
wide variety of essential biological processes by retinoic acid have been performed.  Retinoic 
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acid plays an important role in the regulation of vertebrate embryonic morphogenesis, 
organogenesis, cell growth arrest, differentiation and apoptosis, and homeostasis (11).  For 
example, in Ballim’s study (23), retinoic acid regulates the expression of the gene, TBX3, during 
mouse limb development. TBX3 is a transcriptional repressor that plays an important role in the 
development of the heart, limbs, and mammary glands.  Retinoic acid activates the retinoic acid 
receptor complex to bind at TBX3 promoter and activates endogenous TBX3 expression (23). 
TRANSFAC  
TRANSFAC
®
 is a eukaryotic transcriptional regulation database that contains data 
regarding transcription factors (FACTOR), target genes (GENE), and regulatory binding sites 
(SITE).  It can be used to predict potential transcription factor binding sites.  All sites in the 
database were experimentally defined, and the experimental evidence can be found in SITE in 
the form of the method used and the source (ranging from human to yeast) from which the factor 
was derived (24). 
Eleven different search programs from the open source of TRANSFAC can be found 
online at http://www.gene-regulation.com/pub/programs.html. Match-1.0 Public 
(http://www.gene-regulation.com/pub/programs.html#match) is the program that predicts 
transcription factor binding sites in DNA sequence based on a weight matrix from a library of 
positional weight matrices in TRANSFAC® Public 6.0.  F-Match is a program that identifies 
over-represented transcription factor binding sites. Patch 1.0 (http://www.gene-
regulation.com/pub/programs.html#patch) is the program that predicts transcription factor 
binding sites based on DNA sequence patterns.  P-Match-1.0 Public (http://www.gene-
regulation.com/pub/programs.html#pmatch) is a program that predicts transcription factor 
binding sites using both DNA sequence pattern and weight matrix approaches.  Other programs 
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include AliBaba, CMA (Composite Module Analyst), molwSearch, MatrixCatch, SignalScan, 
SbBlast, and TfBlast (http://www.gene-regulation.com/pub/programs.html).  Since there was no 
RAR or RXR matrix in the TRANSFAC database, Patch (positional weight matrices from 2005) 
was used in this study.   
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Specific Aims 
In this study, we focused on the effect of retinoic acid on human RAI1 expression.  Since 
a recent study on zebrafish in our lab has shown that rai1 in zebrafish is regulated by retinoic 
acid, we hypothesized that the human RAI1 is also regulated by retinoic acid.  In this part of the 
study, we wanted to show that RAI1 expression is enhanced by the treatment of retinoic acid.   
Aim 1 of my study was to determine if retinoic acid upregulates RAI1 and if so to find the 
optimal treatment of retinoic acid to enhance RAI1 expression in cell culture model. We wanted 
to find the treatment that increases RAI1 expression using the least amount of drug and treatment 
time without damaging the cells.  We wanted to increase the expression of RAI1 by about 1.5 
fold to overcome the haploinsufficiency of RAI1 in SMS patients but not to overexpress the gene 
to cause PTLS.   
Aim 2 of my study was to identify if there are RARE binding sites within the upstream 
sequence of RAI1.  We started the search using the Patch program in the TRANSFAC database.  
Then, customized Perl programs, findSeq, which is a sequence-pattern-match based search 
program, and findMotif, which is a motif finding search, were used to repeat the search.  The 
results were compared and analyzed based on DNase I marks on ENCODE and phylogenic 
comparison among different species.     
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Aim I Optimize Retinoic Acid treatment to enhance the Expression of RAI1 via Retinoic 
Acid Induction in Cell Culture Model 
Introduction  
RAI1 is the critical gene that causes SMS and PTLS.  It is a dosage sensitive gene that 
acts as the transcriptional regulator.  However, whether human RAI1 is truly regulated by retinoic 
acid is unknown.   
 Retinoic acid is a member of the retinoid family.  All-trans-retinoic acid is the most 
important endogenous retinoid.  It was used in the treatments of acne and acute promyelocytic 
leukemia with other drugs.  Even though whether retinoic acid regulates RAI1 is unknown, 
studies on other retinoic acid regulated biological processes have been done.  For example, 
vertebrate embryonic morphogenesis, organogenesis, cell growth arrest, differentiation and 
apoptosis, and homeostasis are all regulated by retinoic acids.  Since a recent study on zebrafish 
done by the Elsea lab has shown rai1 in zebrafish is regulated by retinoic acid, we moved on to 
the human RAI1, and tried to prove that the human RAI1 is also regulated by retinoic acid.  In 
this part of the study, we wanted to show that RAI1 expression will be enhanced by the treatment 
of retinoic acid.  We also wanted to find the treatment that use the least amount of retinoic acid 
and the shortest treatment time without damaging the cells to increase the expression of RAI1. 
Hypothesis 
RAI1 expression is regulated by retinoic acid in zebrafish.  Therefore, we hypothesize 
that the expression of RAI1 will be enhanced by the treatment with retinoic acid in a treatment 
time and dose-dependent manner in mammalian cells.  Based on the known kinetics of retinoic 
acid treatment, we hypothesize the combination of 1 hour of treatment and 100 μM of retinoic 
acid will be the optimal treatment to enhance RAI1 expression.  
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Experimental Design 
Culture of the HEK293 cells 
The HEK293T cells used in these experiments were cultured at 37 °C, 5% CO2, under 
standard culture conditions in DMEM (Invitrogen) plus 4.5 g/L D-glucose, L-glutamine, 110 
mg/L sodium pyruvate, 10% FBS, and 1% antibiotic/antimycotic.  Standard protocols for 
maintaining and expanding cells were observed.   
Retinoic acid preparation 
Several different concentrations of all-trans retinoic acid (Sigma) were utilized in these 
studies, ranging from 10 nM to 1 mM.  A 10 mM stock solution of all-trans retinoic acid in 
DMSO was made, aliquoted, and stored at -20 °C until use.  All subsequent retinoic acid 
solutions were made by serial dilutions in DMEM (Invitrogen) plus 4.5 g/L D-glucose, L-
glutamine, 110 mg/L sodium pyruvate, and 20% FBS.  DMSO was used in all control samples.  
Retinoic acid induction treatment  
Treatment of HEK293T cells with retinoic acid was done in standard 6-well plates.  All 
time points and drug concentrations were sampled in duplicate.  Two ml of media containing 
DMSO and/or retinoic acid were placed into each well containing 1 x 10
6 
cells, which were 
plated into the wells 48 hours prior to the treatment.  All samples were incubated at 37 °C, and 5% 
CO2, under standard culture conditions for the time indicated.  Cells were rinsed with PBS, and 
TRIzol reagent (Invitrogen) was added to each well after each time point was done.  Treatment 
details are shown in Table 1.  
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Table 1 Retinoic Acid Induction Treatment Combinations 
Concentration 
(μM retinoic 
acid) 
DMSO 
control (0) 0.01 0.1 1 10 100 1000 
Time  
(min) 30 60 120 30 60 120 30 60 120 30 60 120 30 60 120 30 60 120 30 60 120 
Total number 
of samples  12 12 12 8 8 8 4 4 4 8 8 8 6 6 6 6 6 6 4 4 4 
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Real-time quantitative PCR 
RNA was isolated from the treated samples using the TRIzol reagent/chloroform 
isolation protocol (Invitrogen). All samples were processed independently according to standard 
protocols right after the treatment.  The quality of the isolated RNA was determined by a Thermo 
Scientiﬁc Nanodrop 1000.  RNA concentrations higher than 500 ng/ul were diluted.  cDNA was 
generated from each sample using Qscript according to the manufacturer’s instruction (with 1 ng 
of RNA).  The RAI1 expression in the samples was analyzed using qPCR.  ABI TaqMan probes 
and primers for human mRNA expression were used to detect gene expression for RAI1 and 
GAPDH. All samples were run in triplicate in a 10 ul reaction volume.  QPCR was performed 
using the standard default setting on an ABI Prism 7500 Fast System with GAPDH as an 
endogenous control.  The cycle threshold (Ct) values were determined during the geometric 
phase of the PCR amplification plots as recommended by the manufacturer. Relative fold-
differences of the expression were quantified with the ΔΔCt method as follows: 
ΔCtsample = Avg.Cttarget – Avg.Ctreference 
ΔΔCt = ΔCtsample-test – ΔCtsample-calibrator 
Fold-difference = 2
–ΔΔCt
 
GAPDH was used as an endogenous control (reference) and RAI1 was the target. All expression 
values are calculated relative to control levels set at 1.0. Data were analyzed with Excel, and 
graphs were plotted with GraphPad Prism 4. 
Results 
The retinoic acid induction treatment was repeated six times.  Twenty one different 
combinations of treatment concentrations and time points were used (Table 1).  The expression 
of RAI1 was determined by qPCR.  There were inconsistencies found in the results of all six 
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experiments.  Figure 4 shows the relative fold changes of RAI1 expression of the experiments 
with the higher concentration set, 1000 μM, 100 μM, 1 μM, and 0.01 μM.    
 
Figure 4 RAI1 expression of the higher concentration set 
The figure showed the relative fold changes of RAI1 of the experiments with higher treatment 
concentrations (1000 μM, 100 μM, 1 μM, and 0.01 μM). The left panel shows the relative fold 
changes responded to different treatment times. The right panel shows the relative fold changes 
responded to different treatment concentrations.    
 
For the first retinoic acid induction experiment with the higher concentration set, 1000 
μM, 100 μM, 1 μM, and 0.01 μM, samples with 1000 μM, 100 μM, and 0.01 μM treatments 
showed highest expression at the 1-hour treatment time point, and then the expression decreased 
at the 2-hour treatment time point.  A drug concentration 1 μM showed increased expression 
with increased treatment time.  All four of the drug concentrations showed decreased expression, 
relative to the control, at the 30-min treatment time point.  The 1 μM treatment also showed 
decreased expression, relative to the control, at the 1-hour time point.  Only the 30-min 
treatments showed steady increase in RAI1 expression as the treatment concentration increased.  
Both 1-hour and 2-hour treatments showed dramatic increased expression from 100 μM to 1 mM.   
On the other hand, for the second retinoic acid induction experiment with the higher 
concentration set, the 1 μM and 10 nM treatments showed similar changes in expression over 
different treatment time periods.  They showed overall decreasing in expression relative to the 
control treatment.  The 100 μM treatments showed highest expression at the 1-hour treatment 
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time point, and then the expression decreased at the 2-hour treatment time point.  The 1 mM 
treatment showed highest expression at the 30-min time point and then decreased dramatically at 
the 1-hour time point.  The result for 1 mM treatment at 2-hour time point was missing because 
all of the three samples used in the qPCR were undetectable.   The 2-hour treatment showed 
steady increase in RAI1 expression as the treatment concentration increased in the second 
retinoic acid induction experiment.  The 30-min treatment showed about 6 fold increase from 
100 μM to 1 mM.   The 1-hour treatment showed increase in RAI1 expression as the 
concentration increased from 0.1 μM to 100 μM, and then dropped.  Even though the majority of 
the results of the two experiments were inconsistent, the 100 μM treatment showed similar 
changes in expression over time.   
The large error bars in the higher treatment concentration might reflect that the higher 
concentration of the drug may kill the cells.  The relative fold changes are calculated based on 
the average Ct values of the samples that were done in triplicates. We were missing data points 
when the cell numbers were too low to detect.  When only one or none of the triplicates was 
detected, the calculation might not be accurate.  This could cause the variation in the treatment 
samples and lead to the inconsistent results.  Therefore, the same experiment was repeated again 
with lower drug concentrations.  After we checked the maximum concentration of DMSO that 
can be used in the HEK293 cell culture media, we decide to lower the drug concentration, so the 
most concentrated treatment was changed to 10 μM.  Figure 5 shows the relative fold changes of 
RAI1 expression of the experiments with the lower concentration set, 0.01 μM, 0.1 μM, 1 μM 
and 10 μM. 
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Figure 5 RAI1 expression of the lower concentration set 
The figure showed the relative fold changes of RAI1 of the experiments with the lower treatment 
concentration set (0.01 μM, 0.1 μM, 1 μM and 10 μM). The left panel is the relative fold changes 
responded to different treatment time. The right panel is the relative fold changes responded to 
different treatment concentration.    
 
The results for the treatments with the lower concentration set, 0.01 μM, 0.1 μM, 1 μM 
and 10 μM, showed decreased fold expression compared to the control for the 1 μM and 0.01 μM 
samples.  Only the 0.01 μM treatment showed clear increase of RAI1 expression with increased 
treatment time.  Only the 30-min treatment showed steady increase in RAI1 expression as the 
treatment concentration increased from 0.01 μM to 10 μM.  The 1- and 2-hour treatments 
showed increase of expression after a decreased expression from 0.01 μM to 0.1 μM.    
The combined results of all retinoic acid induction experiment in HEK293 cells are 
shown in Figures 6 and 7.  Figure 6 shows the RAI1 expression responding to different length of 
treatment time.  Figure 7 shows the RAI1 expression in response to different drug concentrations.   
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Figure 6 RAI1 expression in response to different length of treatment time  
Analysis of the relative fold change in expression of RAI1 only showed slight increased response 
to the increasing treatment time.   On average, cells with 1000 μM treatment showed highest 
expression, followed by 10 μM, 100 μM, 0.1 μM, 0.01 μM, control, and 1 μM showed the lowest 
expression.  The error bars indicate the standard error of the mean. 
  
  
Figure 7 RAI1 expression responses to different drug concentration  
The results show overall elevated expression as the treatment concentration increases.  It is 
observed that the range of the error bar, which indicates the standard error of the mean, is also 
increased as the treatment concentration increases.  
 
Overall, the combined results for all six experiments showed little increased expression 
response to the increasing treatment time.  Even though there were changes in experssion level 
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respond to different treatment time, the changes were not significant enough to conclude that the 
experssion of RAI1 is effect by the length of treatment time.  On the other hand, it showed clear 
increased expression response to the increased drug concentration.  The 2-way ANOVA test 
confirmed that only drug concentration was significant in this study (Table 2).  On average, cells 
with 1000 μM treatment showed highest expression, followed by 10 μM, 100 μM, 0.1 μM, 0.01 
μM, control, and then 1 μM.  However, the results showed the range of the error bar also 
increases with increasing treatment concentrations.  
Table 2 Two-way ANOVA test results for retinoic acid induction experiment 
Source of variation % of Total variation P value 
Interaction 3.46 0.9675 
Treatment time 3.02 0.1454 
Concentration  38.33 < 0.0001 
 
Discussion  
HEK293 cell culture has been used as a model system in previous studies on the 
regulatory effects of retinoic acid on the Cyclin C gene, which plays central roles in cell cycle 
regulation and transcription (25).  Makkonen’s study showed that the human Cyclin C gene is 
up-regulated by all-trans retinoic acid.  In our study, the expressions of RAI1 in response to 
retinoic acid at seven different concentrations and three treatment time points were assessed in 
HEK293 cell cultures (Table 1).  We found that retinoic acid did increase RAI1 expression in 
human cells.  The combined data of all of 6 treatment trials showed increased expression 
response to the increasing drug concentration.  However, the patterns of increase in expression 
responding to different treatment concentrations were inconsistent among the six experiments.  
In addition, the results showed increasing range of error bar with increasing drug concentration 
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in each of the six experiments. This finding is consistent with the result that the HEK293 cells 
after the treatment showed loss of adhesion in the higher treatment concentration groups.  One 
possible explanation is that the cell death after the treatment and loss of cells could make the 
qPCR results less reliable and might explain the increase in error bar range and the inconsistency 
of expression patterns.  After the test trials for the 10 μM and 100 μM treatments, the cell 
number for each of the sample was counted (Figure 8).   
 
Figure 8 Cell count before and after treatments with 10 μM and 100 μM retinoic acid 
The red bars indicate the number of cell plated two days before the experiment.  The green bars 
indicate the expected number of cell on the experiment day.  The purple bars indicate the actual 
cell count right after the treatments.  
 
1 x 10
6
 cells/well was plated two days prior to the experiment day.  In theory, the cell numbers 
should be doubled each day, which mean on the experiment day, the cell number should be 4 x 
10
6  
cells/well.  The average cell count after the 10 μM treatments was slightly higher than the 
average cell count after the 100 μM treatments.  The 100 μM treatments showed decrease in cell 
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number as the treatment time increase.  The cell numbers after the 10 μM treatments were more 
uniformly among different treatment length.  However, the cell counts after 10 μM and 100 μM 
treatments were all lower than the expected number.  The low cell count itself could be 
responsible for the low quality of the RNA to start with. In addition, the relative fold changes 
were calculated based on the average Ct values of the samples done in triplicates.  The 
undetectable samples were associated with missing data points when the samples were 
undetectable.  Therefore, when only one or none of the triplicates was detected, the calculation 
might be inaccurate.  If only one sample was detected, the fold-difference was calculated based 
on Ct value of that one sample not the average of the triplicates.  When no sample was detected, 
the data point for that particular treatment was completely lost. This could cause the variation in 
the treatment samples so the results of the experiments were inconsistent.   
To improve the treatment method and get more consistent results, we could repeat the 
treatments with different cell lines and compare the results.  This study did support some of our 
hypothesis.  The expression of RAI1 was enhanced by the treatment with retinoic acid. The 
results showed overall elevated RAI1 expression with retinoic acid treatment.  The concentration 
of the retinoic acid did affect retinoic acid regulation of RAI1.  The result showed overall 
increased expression with increasing treatment concentration.  However, this study found little 
evidence that RAI1 expression was affected by the length of treatment time.  Both the graph and 
the 2-way ANOVA test of the final results confirmed that only the concentration in this 
experiment made significant difference.    
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Aim II Identification of the Retionic Acid Receptor Binding site in RAI1 
Introduction  
Based on previous studies, retinoic acid regulated genes have specific RARE DNA 
sequences in the promoter region of retinoid target genes.  Those sites usually have a consensus 
sequence of ‘(a/g)g(g/t)(g/t)(g/c)a’ separated by five (DR5) or one (DR1) or two (DR2) 
nucleotides.  Retinoic acid receptors will bind those sites in order to regulate the gene expression.   
In this part of the study, we start a search using the Patch program (positional weight 
matrices from 2005) in the TRANSFAC database, and then try to repeat the search using 
customized Perl programs.  All experimentally confirmed RARE sequences data used in this 
study are listed in Appendix A.  The results are compared and analyzed based on number of 
consensus mismatch, halfsite mismatch, DNase I markers and phylogenic comparison among 45 
selected vertebrates.     
Hypothesis 
A retinoic acid receptor binding site is located in the sequence upstream from the start 
codon of RAI1.   
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Methods
 
Figure 9 Workflow to identify possible RARE sites 
More than one search methods were used to identify the possible RARE site in human RAI1. The 
search was started by using the online open source, the Patch program in TRANSFAC database. 
Then the search was repeated using customized perl scripts.  The results of each search methods 
were compared and analyzed.  
Figure 9 shows the workflow to identify possible RARE sites.  Since this is a challenging 
task, more than one search methods were used and the results from each search method were 
compared and analyzed.  
Training sequence collection 
Experimentally confirmed RARE sites of various genes were obtained from literature. 
Appendix A shows the list of experimentally confirmed sites found in literature. The number of 
mismatch between the two half-sites for each of the experimentally confirmed RARE sites was 
calculated using halfSiteMismatch (perl code showed in Appendix B). 
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Figure 10 WebLogo 
WebLogo is a graphical representation of an amino acid or nucleic acid sequence alignment 
developed by Tom Schneider and Mike Stephens.  Each position could potentially contain a 
maximum of 2 bits information for nucleic acid sequence, and 4.32 bits information for amino 
acid sequence.  The overall height of the stack at each position indicates the sequence 
conservation at that position.  The height of symbols within the stack indicates the relative 
frequency of each nucleic acid at that position.  This figure shows the consensus sequence of a 
DR5 RARE site based on the experimentally confirmed sequences collected.  The figure 
suggests the two half sites of the RARE site is highly conserved.   
The list of experimentally confirmed RARE sequences was manually aligned, and the 
WebLogo (Figure 10) was created based on the alignment using the WebLogo website 
(http://WebLogo.berkeley.edu/logo.cgi).  Our consensus sequence is established based on the 
WebLogo.  The number of mismatch between the consensus sequence and each of the 
experimentally confirmed RARE sites was calculated using consensusMismatch (perl code 
shown in Appendix C). 
Patch search 
The nucleotide sequence of human (hg19, Feb. 2009) RAI1, including 5,000 bases 
upstream from exon 1 and up to the first coding exon (exon 3), was obtained from Genome 
Browser.  The sequence was searched in Patch public 1.0 using the default settings shown in 
Table 2. The results were filtered with human identifiers of RAR or RXR binding factors.  The 
remaining hits were analyzed by position.  The hits with another hit next to it and separated by 1, 
2, or 5 bases were kept for further analysis. 
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 The positions of the candidate hits were compared with the DNase I mark position 
(data obtained from ENCODE project via Genome Browser, GEO sample accession, 
GSM1008578).  The number of mismatch between our own consensus sequence and each 
matched sequence was calculated. The number of mismatch between the two half-sites for each 
matched sequence was also calculated.   
Table 3 Patch Searching Parameters 
Site selection  Vertebrates 
min length of sites 6 
max number of mismatches 2 
mismatch penalty 100 
lower score boundary 87.5 
 
Perl Search 
FindSeq Search 
The nucleotide sequence of human (hg19, Feb. 2009) RAI1, including 5,000 base 
upstream from exon 1 up to the first coding exon (exon 3), was obtained from Genome Browser.  
The 116,460 base-pair long sequence was searched in a sequence search based on a customized 
Perl program (code shown in Appendix D).   The relaxed half-site consensus sequence, 
“(a/g)g(g/t)(g/t)(g/c)a” (separated by 1, 2, or 5 nt), that was found in the literature, was used as 
the search pattern first (results showed under oldFindSeq in the result section). Then the search 
was repeated using the more strict consensus sequence (results shown under newFindSeq in the 
result section), "(a/g)g(g/t)tca” (separated by 1, 2, or 5 nt), shown in the WebLogo (Figure 10). 
The position of the candidate hits was compared with the DNase I mark position (data obtained 
from ENCODE project via Genome Browser, GEO sample accession, GSM1008578).  The 
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number of mismatch between our own consensus sequence and each matched sequence was 
calculated. The number of mismatch between the two half-sites for each matched sequence was 
also calculated.      
FindMotif Search 
Since the longest spacing for the experimentally confirmed RARE site sequence is DR5, 
the alignment of the experimentally confirmed RARE site sequence was used as the input file of 
the FindMotif program (code shown in Appendix E), which is the motif search based on 
customized Perl program, to calculate the position-specific scoring matrix (PSSM) for the DR5 
search only.  The alignment file was manually edited to fit the criteria for the DR1 and DR2 
searches.  The nucleotide sequence of human (hg19, Feb. 2009) RAI1, including 5,000 base 
upstream from exon 1 up to the first coding exon (exon 3), was obtained from Genome Browser.  
The 116,460 base-pair long sequence was searched in the FindMotif program to find the 
sequences that PSSM fits best.  The output of the FindMotif program shows the top 100 hits.  
Sequences with scores higher than 1 (scores expressed as a log-odds ratio relative to a random 
model using the base of the natural logarithm) are therefore ~2.7 times more likely to have arisen 
from the PSSM model than by chance, and were therefore considered possible candidates.  The 
alignment of the experimentally confirmed RARE site sequence was reversed and complemented 
using the reverseMotif program (code shown in Appendix F).  The reverse compliment 
alignment was used as the input file to find the possible RARE sites on the complementary 
strand. 
The positions of the candidate hits were compared with the DNase I mark position (data 
obtained from ENCODE project via Genome Browser, GEO sample accession, GSM1008578).  
The number of mismatch between our own consensus sequence and each matched sequence was 
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calculated. The number of mismatch between the two half-sites for each matched sequence was 
also calculated.   
Compare and combine results from the four searches  
The results of the Patch search and the Perl search were compared. The sites found in 
more than one searches were considered more likely to be real RARE sites. Motif conservation 
was then analyzed on the basis of MultiZ alignments between the human and other 45 
vertebrates’ genomic sequences (including Alpaca, Armadillo, Baboon, Bushbaby, Cat, Chicken, 
Chimp, Cow, Dog, Dolphin, Elephant, Fugu, Gorilla, Guinea Pig, Hedgehog, Horse, Kangaroo 
rat, Lamprey, Lizard, Marmoset, Medaka, Megabat, Microbat, Mouse, Mouse lemur, Opossum, 
Orangutan, Pika, Platypus, Rabbit, Rat, Rhesus, Rock hyrax, Shrew, Sloth, Squirrel, Stickleback, 
Tarsier, Tenrec, Tetraodon, Tree Shrew, Wallaby, X. tropicalis, Zebra finch, and Zebrafish) . The 
sites found in more than one search (Table 7) were checked for conservation in the selected 
vertebratesb to determine if the region encompassing the motif in human is aligned with a 
genomic region in zebrafish, mouse, and/or rat that also contained a ‘(a/g)g(g/t)(g/t)(g/c)a’ DR1, 
DR2, or DR5 motif.  The alignment was downloaded at Genome Browser 
(http://hgdownload.soe.ucsc.edu/downloads.html). 
Results 
Patch 
 The raw Patch output (data not shown) was filtered by only keeping the matches with 
human identifiers of RAR or RXR binding factors with positions found next to another match 
and separated by 1, 2, or 5 bases.  A total of 65 sites found in the Patch search match the RARE 
criteria, the results are shown in Appendix E.  There were 22 out of 65 sites found within the 
range of the number of consensus mismatch (had 0 to 5 mismatches to consensus) and half-site 
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mismatch (had 0 to 3 mismatches between the two half sites) based on the experimentally 
confirmed RARE sequences.  Table 4 shows the start positions, distance from the transcriptional 
start site, strand, and the matching sequences of the 22 sites.  Table 4 also shows whether the 22 
sites within the DNase I hypersensitive site (DHSs).  The ENCODE data were obtained from 
Genome Bowser (GEO sample accession, GSM1008578). The DNase I hypersensitive site 
sequencing was done on frozen frontal cerebrum tissue from NICHD donor by Duke University. 
The number of mismatch from the consensus and the number of mismatch between the half sites 
are also shown in Table 4. Three out of the 22 sites are true direct repeats, which highlighted in 
yellow in Table 4.  Eleven out of the 22 sites are within the DHSs.
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Table 4 Final Patch Result 
StartPos. 
Dis. 
 (kb) Str. halfSite1   halfSite2 
within  
DHSs 
consensus 
mismatch 
halfSite 
mismatch 
chr17: 17581163 -3.624 + AGGTCA ----- GGGTCA 
 
2 1 
chr17: 17581174 -3.613 - TGACCC ----- TGACCT 
 
2 1 
chr17: 17589242 4.455 - AGGGAG -- AGGTGA + 5 3 
chr17: 17604612 19.825 + TGCACT -- TGCCCT + 2 1 
chr17: 17606566 21.779 + GGGTCA -- AGGACA + 3 2 
chr17: 17610723 25.936 + AGGTGA - AGGTGA   3 0 
chr17: 17614711 29.924 + TGCCCT - TCCCCC 
 
5 2 
chr17: 17620363 35.576 - TGGACT -- TGACCT 
 
1 2 
chr17: 17620761 35.974 - TGCCCT -- TCACCC 
 
4 3 
chr17: 17627149 42.362 + TTACCT -- TGACCC + 3 2 
chr17: 17628863 44.076 - TGACCC ----- TCCCCC + 5 2 
chr17: 17641675 56.888 + GGTTCA ----- GGGTGA + 5 2 
chr17: 17643193 58.406 - AGGTGA -- AGGTCA + 2 1 
chr17: 17656406 71.619 - TGACCC -- TGCCCT + 3 2 
chr17: 17665427 80.64 + TGGACT - TGCCCT + 2 2 
chr17: 17680497 95.71 - TGCCCT - TAACCT 
 
3 2 
chr17: 17684302 99.515 - AGGGGA -- GGGTGA + 5 2 
chr17: 17688312 103.525 - GGGAGA -- AGGTGA + 5 2 
chr17: 17693313 108.526 + GGTTCA - AGGTCA 
 
3 2 
chr17: 17693320 108.533 - TGACCT - TGAACC 
 
3 2 
chr17: 17694566 109.779 + TGCCCT ----- TGCCCT   3 0 
chr17: 17694900 110.113 - AGGGGA - AGGGGA   5 0 
CONSENSUS SEQUENCE 
+ AGGTCA  AGTTCA    
- TGAACT  TGACCT    
 
    
 
34 
 
 
Figure 11 illustrates the locations of the 22 sites along RAI1.  Two of them were found upstream 
of exon 1, 8 of them were found in intron 1, and 12 sites were found in intron 2.  Among those 
22 sites, 10 were found on the + strand, the strand on which RAI1 is located, 12 were on the 
complementary strand.  Seven out of the 22 sites were DR1, 10 were DR2, and 5 were DR5.   
 
Figure 11 Locations of Patch results  
The black line indicates RAI1.  The black boxes along the line indicate the 6 exons. The black 
arrow indicates the transcriptional start site.  The positions of the hits relative to the 
transcriptional start site are shown with the strand indicated in the parenthesis. The red ones 
indicate the matches also found by other search method(s). 
 
OldFindSeq 
A total of 50 sites were found by findSeq, which is the customized Perl program based on 
a Perl script originally written by Dr. Jeff Elhai for the class BNFO601, using the relaxed half-
site consensus sequence, “(a/g)g(g/t)(g/t)(g/c)a” (separated by 1, 2, or 5 nt), that was found in the 
literature. The results are shown in Appendix H.  The expected number of hits, found in a 
sequence with the same nucleotide distribution and length as the searched sequence using the 
consensus sequence used in the search, was 12.99.  There were 35 out of the 50 sites found 
within the range of the number of consensus mismatch (had 0 to 5 mismatches to consensus) and 
half-site mismatch (had 0 to 3 mismatches between the two half sites) based on the 
experimentally confirmed RARE sequences.  Table 5 shows the start positions, distance from the 
transcriptional start site, strand, matching sequences, whether within the DHSs, consensus 
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mismatch, and the mismatch between the half sites. Four out of the 35 sites are true direct repeats, 
and these are highlighted in yellow in Table 5.  Fifteen out of the 35 sites lie within the DHSs. 
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Table 5 Final Results for oldFindSeq search 
StartPos. 
Dis. 
(kb) Str. halfSite1   halfSite2 
within  
DHSs 
consensus 
Mismatch 
halfSites 
Mismatch 
chr17: 17581163 -3624 + AGGTCA ccaag GGGTCA  2 1 
chr17: 17582877 -1910 + AGGTCA gg AGTTCA  0 1 
chr17: 17583517 -1270 - TCCCCT c TGCCCT  4 1 
chr17: 17589217 4430 - TCCACC tggga TGCCCC  5 2 
chr17: 17590664 5877 + GGGGGA ag AGTGGA  5 2 
chr17: 17596741 11954 - TCCCCT ccccg TGCCCC + 5 2 
chr17: 17600371 15584 - TGCCCT tgccc TGACCT + 2 1 
chr17: 17604612 19825 - TGCACT gc TGCCCT + 2 1 
chr17: 17604862 20075 - TCCCCT ttccc TCCCCT + 5 0 
chr17: 17608667 23880 + GGTGCA gt GGGTCA  5 2 
chr17: 17609703 24916 + AGGGCA tgcat AGGTGA  3 2 
chr17: 17610723 25936 + AGGTGA c AGGTGA   3 0 
chr17: 17614711 29924 - TGCCCT g TCCCCC  5 2 
chr17: 17618427 33640 + GGGTGA gc AGGGGA  5 2 
chr17: 17620753 35966 + GGGTGA gc AGGGCA  4 3 
chr17: 17628852 44065 + GGGGGA ccacc GGGTCA + 5 2 
chr17: 17628929 44142 + AGGGGA ga GGTGGA + 5 2 
chr17: 17629039 44252 - TGCCCC c TCCCCT + 5 2 
chr17: 17631247 46460 - TGCCCC c TCCCCT  5 2 
chr17: 17641675 56888 + GGTTCA gggct GGGTGA + 5 2 
chr17: 17641841 57054 + 
GGGTGA 
aggc
g 
GGGGCA + 
5 2 
chr17: 17642972 58185 - TGACCT ctggc TGCCCC + 3 2 
chr17: 17643185 58398 - TGACCT tg TCACCT + 2 1 
chr17: 17648079 63292 + GGGTGA ca GGTTGA  4 1 
chr17: 17656398 71611 + AGGGCA ct GGGTCA + 3 2 
chr17: 17658101 73314 + AGGGCA ag GGTGCA  3 2 
chr17: 17665765 80978 + GGTTCA aattt AGTTGA  3 2 
chr17: 17666024 81237 + GGGGCA ggtag AGGTGA + 4 3 
chr17: 17675694 90907 - TCCCCT c TCACCC  5 2 
chr17: 17679489 94702 + GGGGGA aactg AGGTCA  4 3 
chr17: 17684294 99507 - TCACCC cc TCCCCT + 5 2 
chr17: 17693313 108526 + GGTTCA a AGGTCA  3 2 
chr17: 17694566 109779 - TGCCCT gggct TGCCCT   3 0 
chr17: 17694893 110106 - TCCCCT a TCCCCT   5 0 
chr17: 17695284 110497 - TGCCCC agccc TCACCT + 4 3 
CONSENSUS SEQUENCE 
+ AGGTCA  AGTTCA    
- TGAACT  TGACCT    
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Figure 12 illustrates the locations of the 35 sites along RAI1.  Twenty two of them were 
found on the + strand, and 13 were on the complement strand.  One out of the 8 sites was DR1, 
12 were DR2, and 15 were DR5.   
 
Figure 12 Locations of oldFindSeq results 
The black line indicates RAI1.  The black boxes along the line indicate the 6 exons. The black 
arrow indicates the transcriptional start site.  The positions of the hits relative to the 
transcriptional start site are shown with the strand indicated in the parenthesis. The red ones 
indicate the matches also found by other search method(s). 
 
NewFindSeq 
A total of 3 sites found by the findSeq using the more stringent half-site consensus 
sequence, “(a/g)g(g/t)tca” (separated by 1, 2, or 5 nt).  The results are shown in Table 6.  The 
expected number of hits found, in a sequence with the same nucleotide distribution and length as 
the searched sequence with the same consensus sequence used in the search, was 0.63.  None of 
the 3 hits are within the DHSs.    All 3 sites found within the range of the number of consensus 
mismatch (had 0 to 5 mismatches to consensus) and half-site mismatch (had 0 to 3 mismatches 
between the two half sites) based on the experimentally confirmed RARE sequences.  Table 6 
shows the start positions, distance from the transcriptional start site, strand, matching sequences, 
whether within the DHSs, consensus mismatch, and the mismatch between the half sites. None 
of the 3 hits are true direct repeats 
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Table 6 Final Results for newFindSeq search 
StartPos. 
Dis. 
(kb) str. halfSite1   halfSite2 
within  
DHSs 
consensus 
Mismatch 
halfSites 
Mismatch 
Chr17: 17582877 -1910 + AGGTCA gg AGTTCA 
 
0 1 
Chr17: 17581163 -3624 + AGGTCA ccaag GGGTCA 
 
2 1 
Chr17: 17693313 108526 + GGTTCA a AGGTCA   3 2 
CONSENSUS SEQUENCE 
+ AGGTCA  AGTTCA    
- TGAACT  TGACCT    
 
Figure 13 illustrates the locations of the 3 sites along RAI1.  All 3 were found on the + strand.  One site was DR1, 1 was DR2, 
and 1 was DR5.   
 
Figure 13 Locations of the newFindSeq results 
The black line indicates RAI1.  The black boxes along the line indicate the 6 exons. The black arrow indicates the transcriptional start 
site.  The position of the hits relative to the transcriptional start site is shown with the strand indicated in the parenthesis. The red ones 
indicate the matches also found by other search methods.
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FindMotif 
The FindMotif program shows the top 100 hits for each search and DR1, DR2, and DR5 
sites for both of strands which need to be searched separately.  A list of 600 sites that match the 
PSSM calculated based on the input alignments (Appendix A) was generated.  There are 245 hits 
with scores, which are log-odds ratio relative to natural model, higher than 1 (Appendix I).  The 
start positions, distance from the  transcriptional start site, strand, matching sequences, whether 
within the DHSs, consensus mismatch, and the mismatch between the half sites are shown in 
Appendix I.  Appendix I also shows a score for each hit.  The higher the score, the more likely 
the hits have been produced by our model of RARE than by random association of nucleotides.  
However, the scores are calculated based on the given training sequence (input alignment), and 
each time the training set changes, the scores change too.  So the scores can only be compared 
within each search (e.g. scores to the DR5+ strand can only be compared to DR5+. not DR5- or 
DR2+).  There are 169 out of the 245 sites found within the range of the number of consensus 
mismatch (had 0 to 5 mismatches to consensus) and half-site mismatch (had 0 to 3 mismatches 
between the two half sites) based on the experimentally confirmed RARE sequences, 47 of them 
are DR1, 73 are DR2, and 49 are DR5. Only 2 of the 169 hits are true direct repeats, and 52 of 
them lie within the DHSs.     
Results Comparison  
 The results of all four search methods were compared.  The hits that showed up in more 
than one search method are listed in Table 7.   Twenty three hits were found in more than one 
search methods.   The positions of the 23 hits are shown in Figure 14.  Fifteen of them were 
found on the + strand, 8 were found on the – strand.  Three out of the 23 hits were found 
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upstream of the transcriptional start site, 7 were found in intron 1, and 13 were found in intron 2.  
 
Figure 14 Locations of the matches found in more than two searches  
The black line indicates RAI1.  The black boxes along the line indicate the 6 exons. The black 
arrow indicates the transcriptional start site.  The position of the hits relative to the 
transcriptional start site is shown with the strand indicated in the parenthesis.  The red lines 
indicate the hits found by all 4 search methods, and the blue lines indicate the hits shown high 
conservation in mouse and/or rat.  
 
The 3 hits that highlighted in yellow in Table 7 were found by all four searches.  Twelve 
were found with in the DHSs.  Six of them are DR1 sequence, 9 are DR2, and 8 are DR5.  Three 
out of the 23 hits are true direct repeats, the other 20 hits all have numbers of mismatch between 
the half sites within the range found in the collected RARE sequences. Twenty one out of 23 hits 
have a number of consensus mismatch within the range found in the collected RARE sequences. 
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Table 7 Summary for All for Search Methods 
                                                          
1 OFS – FindSeq search using the relaxed consensus sequence 
2 NFS – FinsSeq search using the stringent consensus sequence 
3 FM – FindMotif search 
4 Patch – the TRANSFAC Patch search 
No. StartPos. 
Dis.  
(kb) Str. halfSite1   halfSite2 
within  
DHSs 
consensus 
Mismatch 
halfSites 
Mismatch 
OFS
1
 
NFS
2
 
FM
3
 
Patch
4
 
1 Chr17: 17581163 -3.624 + AGGTCA ccaag GGGTCA 
 
2 1 + + + + 
2 Chr17: 17581174 -3.613 + GGGTCA ca AGCTGA 
 
3 3 
  
+ + 
3 Chr17: 17582877 -1.91 + AGGTCA gg AGTTCA 
 
0 1 + + + + 
4 Chr17: 17600371 15.584 - TGCCCT tgccc TGACCT + 2 1 + 
 
+ 
 5 Chr17: 17604612 19.825 - TGCACT gc TGCCCT + 2 1 + 
 
+ + 
6 Chr17: 17606566 21.779 + GGGTCA gg AGGACA + 3 2 
  
+ + 
7 Chr17: 17610723 25.936 + AGGTGA c AGGTGA  3 0 + 
  
+ 
8 Chr17: 17614711 29.924 - TGCCCT g TCCCCC  5 2 + 
  
+ 
9 Chr17: 17620753 35.966 + GGGTGA gc AGGGCA  4 3 + 
  
+ 
10 Chr17: 17627149 42.362 - TTACCT cc TGACCC + 3 2 
  
+ + 
11 Chr17: 17628852 44.065 + GGGGGA ccacc GGGTCA + 5 2 + 
  
+ 
12 Chr17: 17641675 56.888 + GGTTCA gggct GGGTGA + 5 2 + 
 
+ + 
13 Chr17: 17642972 58.185 - TGACCT ctggc TGCCCC + 3 2 + 
 
+ 
 14 Chr17: 17643185 58.398 - TGACCT tg TCACCT + 2 1 + 
 
+ + 
15 Chr17: 17654082 69.295 - TCACCC c TGACTC 
 
7 2 + 
 
+ 
 16 Chr17: 17656398 71.611 + AGGGCA ct GGGTCA + 3 2 + 
 
+ + 
17 Chr17: 17665427 80.64 - TGGACT c TGCCCT + 2 2 
  
+ + 
18 Chr17: 17665765 80.978 + GGTTCA aattt AGTTGA 
 
3 2 + 
 
+ 
 19 Chr17: 17672076 87.289 + AGTGCA tggga GGGGGA + 6 3 + 
  
+ 
20 Chr17: 17684294 99.507 - TCACCC cc TCCCCT + 5 2 + 
  
+ 
21 Chr17: 17693313 108.526 + GGTTCA a AGGTCA 
 
3 2 + + + + 
22 Chr17: 17694566 109.779 - TGCCCT gggct TGCCCT  3 0 + 
  
+ 
23 Chr17: 17694893 110.106 - TCCCCT a TCCCCT   5 0 +     + 
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Figure 15 Alignment of the top 10 organism that have conserved RARE sequence  
Conservation of the 23 hits shown in more than one search methods was analyzed. The matched RARE sites sequences are indicated 
by boxes.  The alignments, with 15 bp upstream and downstream from the matched RARE sequence, of the top 10 organisms of each 
hits are shown in the figure. Noted that hit No. 3 did not have 10 alignments; it only had the organism shown in the alignment with 
conserved sequence at that position, others might have more than 10 organisms with conserved sequence at that position.  
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All 23 hits showed conserved sequence at the position of some selected vertebrates.  Hit 
No. 3 only showed conservation in 5 out of 45 selected vertebrates.  The remaining 22 hits all 
showed conservation in more than 10 out of 45 selected vertebrates.   The alignments of the top 
10 organisms are shown in Figure 15.    
 
Figure 16 Human vs. mouse and rat Alignments 
Figure shows the alignments of the 13 hits that have conserved sequences with mouse and/or rat 
in the possible RARE site region.  The coordinates of the sequence alignments shown are at the 
beginning and the end of the sequences.  Four (No. 4, 10, 11, and 22) out of the 13 hits have high 
conservation with both mouse and rat at the two RARE half sites. Three (No. 7, No. 14, and 21) 
of them have high conservation with rat, and one (No. 12) have high conservation with mouse at 
the two RARE half sites.    
 
Thirteen out of the 23 hits shown in Table 7 found conservation with mouse and/or rat.  
The alignments, with only mouse and rat, are shown in Figure 16.  Hit No. 4, 10, 11, and 22 
showed high conservation with both mouse and rat at the two RARE half sites.  Hit No. 4 
showed 58% conservation with mouse, and 67% conservation with rat at the two RARE half 
sites. Hit No. 10 showed 83% conservation with both mouse and rat at the RARE site.  Hit No. 
11 showed 83% conservation with rat, 92% conservation with mouse at the two half sites. Hit No. 
22 showed 92% conservation with both mouse and rat at the two half sites.  Hit No. 7, No. 14, 
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and 21 also had high conservation with rat (58%, 75% and 83%), and No. 12 showed high 
conservation with mouse (75%) at the two RARE half sites. 
Discussion  
Since the retinoic acid molecules cannot bind directly to the target genes, they bind to 
transcription factors called retinoic acid receptors first.  Target genes regulated by retinoic acid 
have specific RARE sequences in the promoter region.  Finding RARE sites in the promoter 
region of RAI1 may support the hypothesis that RAI1 is regulated by retinoic acid.  Therefore we 
hypothesize that a retinoic acid receptor binding site is located in the sequence upstream from the 
transcriptional start site of RAI1. 
We found 65 sites using Patch search.  Patch is a program based on TRANSFAC 
database that predicts transcription factor binding sites based on DNA sequence patterns.  It is an 
easy program to use, and it has free access online.   However, it does not have flexible options 
for search settings.  It cannot search the sites based on specific organisms, it only has options 
such as vertebrates, fungi, or plants, and it doesn’t allow the user to select the specific 
transcription factors we wish to search for.  Other settings include minimum length of sites, 
maximum number of mismatch, mismatch penalty, and lower score boundary.  As the result of 
inflexible setting options, the program outputs a massive number of “matched sites”.  Those 
“matched sites” correspond to “possible binding sites” for all of the transcription factors that in 
the database.  Therefore, for our search, the results were filtered; we only kept the results with 
human identifiers of RAR or RXR binding factors.  Other disadvantage of using Patch for our 
search is that RARE sites contain two half sites that are separated by 1, 2, or 5 bases.  Patch can 
only search for all the half sites, but not the combination as a whole. Therefore, the remaining 
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hits were then analyzed by position.  The hits with another hit next to it and separated by 1, 2, or 
5 bases were kept for further analysis. 
Since Patch cannot be specified to search for RARE sites only, we wrote our own 
customized Perl program, FindSeq.  The FindSeq program is also a sequence pattern based 
search.  We initially used the relaxed consensus sequence, “(a/g)g(g/t)(g/t)(g/c)a”, found in the 
literature as the search pattern (22).  Fifty sites were found using this pattern.  Then we repeated 
the search with our own consensus sequence, “(a/g)g(g/t)tca”,   that was found based on the 
published experimentally confirmed RARE sequences.  Only three sites were found because our 
own consensus sequence is much more strict than the one in literature.  Since the search pattern 
is given to the FindSeq program, it is hard to decide how relaxed the pattern should be.  If the 
search pattern is too relaxed, such as the consensus sequence found in literature, too many hits 
are found.  If the search pattern is too strict, it might miss other possible sites.     
We also wrote another customized Perl program, FindMotif.  FindMotif is a motif-based 
search.  It calculates the position-specific scoring matrix (PSSM) based on the alignment of 
experimentally confirmed RARE sequences and finds sequences that PSSM fits best.  Since the 
longest spacing for the experimentally confirmed RARE sequences we found is DR5, the 
alignment of those sequences also has 5 nucleotides in between the half sites. Therefore, the 
FindMotif finds only the possible DR5 sites in the target sequence.  To find the DR1 and DR2 
sites, we manually changed the alignment to fit the DR1 and DR2 criteria.  The FindMotif 
program outputs the top 100 hits and a score for each of the hits.  However, a high score alone 
does not indicate the hit is a good candidate for RARE sites.  Like the previous search methods 
mentioned, one of the disadvantages is the search does not consider the fact that RARE site 
contains two half sites that are direct repeat of each other.   
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We also used DNase I marks to analyze the results from the four search methods.  The 
DNase I marks indicate the regions of chromatin which are sensitive to cleavage by the DNase I 
enzymes.  The chromatin of these regions loses its condensed structure and exposes its DNA so 
the factors can bind.  If the position of the sites we found overlap with the position of DNase I 
marks, it's more likely that the site to be correspond to active regulatory regions.  Twenty three 
sites were found by more than one search method.  Twelve of these sites overlap with the 
position of a DNase I mark.  However, this does not exclude matches found outside the DHSs as 
real sites.  Hit. No. 3 (Table 7, found by all four search methods), which is not within the DHSs, 
was also found by Laperriere’s team, and confirmed to be a real RARE site by ChIP assay (26).  
In principal we could also use the ENCODE ChIP-on-chip data of retinoic acid-treated human 
HL60 cells to analyze our results to see if they were found within the binding regions for RARα 
like Laperriere’s team did (26).  Unfortunately, the HL60 data don’t include chromosome 17, 
which is the location of RAI1. 
The conservation, at the position of the hits, between human and other 45 selected 
vertebrates was assessed.  Since many of the experimentally confirmed RARE sites have nearly 
identical sequence in mouse and/or rat, the hits that have highly conserved sequence at the same 
position in mouse and/or rat are considered more likely to be real RARE sites.  We also looked at 
the conservation in zebrafish because it is a commonly used animal model and the unpublished 
data from Elsea’s lab showed elevated Rai1 expression after treatment in zebrafish with retinoic 
acid.  However, none of the hits that were found by more than one search methods showed 
conservation in zebrafish. 
In this study, three hits (Table 7, No. 1, 3, and 21) were found by all four search methods.   
However, no conservation was found in mouse or rat for hit No. 1.  None of the three hits is 
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coincident with DHSs. However, Hit No. 3 was confirmed to be a real RARE site by 
Laperriere’s team.  All three hits have number of consensus mismatch and half-sites mismatch 
lower than 4 (the consensus mismatches found in the experimentally confirmed ones are ranged 
from 0 to 5, and the mismatches between half sites in the experimentally confirmed ones are 
ranged from 0 to 3). Hit No. 21 showed 83% conservation at the two RARE half sites in rat.  All 
three hits score at the top of their respective FindMotif searches.  
 Other than hit No. 3 and 21, Hit No. 4, 7, 10, 11, 12, 14, and 22 were also strong 
candidates.  Hit No, 12 and 14 were found by 3 out of the 4 search methods used, and Hit No. 4,  
7, 10, 11, and 22 were found by 2 of the search methods used.  All 6 of them found high 
conservation at the in mouse and/or rat.  Hit No. 7 and 22 are true direct repeat, while the other 5 
all have a number of mismatch relative to the consensus sequence and number of  mismatch 
between the two half sites within the range found in the experimentally confirmed RARE sites. 
It is essential to bear in mind that the identification and analysis of the possible RARE 
sites was only computer based.  Further experiments will be needed to confirm those sites as real 
RARE sites.  One area of possible future research is to confirm that the RARE sites selected in 
silico are able to bind RAR/RXR heterodimers using electrophoretic mobility shift assay or ChIP 
assay. 
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Conclusion and Future Study 
 The expressions of RAI1 in response to retinoic acid at seven different concentrations and 
three treatment time points were assessed in HEK293 cell cultures (Table 1).  Retinoic acid is a 
type of retinoid and a derivative of vitamin A.  A previous study in the Elsea lab on zebrafish 
showed that retinoic acid induces the up-regulation of rai1.  In our study, we found that retinoic 
acid did increase RAI1 expression in human cells.  The combined data of all six treatment trials 
showed increased expression response to the increasing drug concentration.  However, the 
patterns of increase in expression responding to different treatment concentrations were 
inconsistent among the six experiments.  In addition, the results showed an increasing range in 
the error bar with increasing drug concentration in each of the six experiments. This finding is 
consistent with the result that the HEK293 cells after the treatment showed loss of adhesion in 
the higher treatment concentration groups, and this is possibly a significant confounding factor.  
The large error bars in higher treatment concentration might also reflect that the higher 
concentration of the drug may kill the cells.  The low cell count itself could be responsible for 
the low quality of the RNA, as RAI1 would not be appropriately expressed in dead cells.  Since 
we were unable to separate the dead cells from the live ones in the samples, the qPCR results 
might be affected.  In addition, the relative fold changes were calculated based on the average Ct 
values of the samples performed in triplicates. Data points were missing because the low quality 
samples were undetectable.  When only one or none of the triplicates was detected, the 
calculation will not be accurate.  This could easily cause the observed variation in the treatment 
sample and explain why the results of the two experiments were inconsistent.   
We lowered the treatment concentration to avoid the cytotoxic effect of the drug.  
However, we were unable to identify an ideal concentrations result with consistent change of 
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expression level.  To improve the treatment method and get more consistent results, we could 
repeat the treatment with different cell lines and compare the results.   
 Since retinoic acid molecules cannot directly bind to the target genes, transcription 
factors called retinoic acid receptors first bind the retinoic acid.  Target genes that are regulated 
by retinoic acid have specific RARE sequences in the promoter and 5’-UTR regions.  Finding 
RARE sites in the promoter and/or 5’-UTR region of RAI1 would support the hypothesis that 
RAI1 is regulated by retinoic acid.  In this study, 9 strong possible RARE sites were found 
upstream of the first coding exon of human RAI1 based on four search methods, DNase I mark 
data, and conservation in 45 other vertebrates (Figure 14, indicated by red and blue lines).  Even 
though only one of the strong candidates is a true direct repeat, which is an important 
characteristic of RARE sites described by literature, they still could be real RARE sites.  In our 
review of the literature, we found 45 experimentally confirmed RARE sites in human genes, only 
4 of are true direct repeats (Appendix A).  The other 41 sites have mismatch of the two half sites 
ranging from 1 to 3 nucleotides.  All 9 strong candidates we found have a number of mismatched 
bases within this experimentally observed range.  None of the 23 hits that were identified by 
more than two search methods have more than 3 mismatches between the two half sites.   
Our identification and analysis of possible RARE sites was only computer based.  Further 
biological experiments are needed to confirm these as real RARE sites.  One possible future 
research study is to confirm that the RARE sites selected in silico are able to bind RAR/RXR 
heterodimers.  One way we could do that is to perform an electrophoretic mobility shift assay 
(EMSA).  We could mix the RAR/RXR heterodimers with the upstream RAI1 sequence we 
assessed to see if they bind to the sequence.  Another way we can confirm is to perform a ChIP 
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experiment using RAR antibodies.  Since RXR also bind transcription factors other than RAR, 
using RXR antibodies might also find binding sites other than RARE sites.  
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Appendix A:  Experimentally confirmed RARE sites 
 
Gene halfSite1   halfSite2 
consensus 
mismatch 
halfSite 
mismatch 
Reference 
CYP26A1 AGTTCA ctcgg ATGTCA 3 2 
Zhang 2010 (27) 
CYP26A1_2 GGGTCA caggc GGGTCA 3 0 
RARB GGTTCA ccgaa AGTTCA 2 1 
Umesono 1991 (28) 
ADH3 GGGTCA ttcag AGTTCA 1 2 
Pitx2 AATTCA ttagt GAATCA 5 2 Kumar 2010 (29) 
TBX2 AGATCA cgaca AGATCT 3 0 Sakabe 2012 (30) 
RARa2 GGGTCA ccgaa AGTTCA 1 1 
Lehmann 1992 (31) 
RARy2 GGGTCA ggagg AGGTGA 3 2 
Pref-1 GGGTCA ga AGCCCA 3 3 
Berry 2012 (32) SOX9 AGTCCA agtca AGGGCC 5 3 
KLF2 AGTCCA agtca AGGGCC 5 3 
HOXA1 GGTTCA ccgaa AGTTCA 2 1 Langston 1997 (33) 
Hig1a GGGTCA atg GGGTCA 3 0 Amati 2010 (34) 
GPRC5A_1 AGGTCA gg AGTTCA 0 1 
 Laperriere 2007 
(26) 
GPRC5A_2 AGGTCA gg AGTTCA 0 1 
GPRC5A_3 AGGTCA gg AGTTCA 0 1 
RAI1_1 AGGTCA gg AGTTCA 0 1 
RAI1_2 AGGTCA gg AGTTCA 0 1 
RARRES1_1 AGGTCA gg AGTTCA 0 1 
RARRES1_2 AGGTCA gg AGTTCA 0 1 
RARRES1_3 AGGTCA gg AGTTCA 0 1 
RARRES1_4 AGGTCA gg AGTTCA 0 1 
RARRES3_1 AGGTCA gg AGTTCA 0 1 
RARRES3_2 AGGTCA gg AGTTCA 0 1 
SMYD5_1 AGGTCA gg AGTTCA 0 1 
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SMYD5_2 AGGTCA gc AGTTCA 0 1 
SMYD5_3 AGGTCA gg AGTTCA 0 1 
HBD AGGTCA gg AGTTCA 0 1 
HBG1 AGGTCA ag AGTTCA 0 1 
HBG2 AGGTCA ag AGTTCA 0 1 
CATSPER2 AGGTCA gg AGTTCA 0 1 
PDIA3 AGGTCA gg AGTTCA 0 1 
LILRA5 AGGTCA gg AGTTCA 0 1 
RNPC2_1 AGGTCA gg AGTTCA 0 1 
RNPC2_2 AGGTCA gg AGTTCA 0 1 
DONSON AGGTCA ga AGTTCA 0 1 
C6orf148 AGGTCA gg AGTTCA 0 1 
OSTM1 AGTTCA gg AGTTCA 1 0 
CAV1 AGGTCA gg AGTTCA 0 1 
KIAA0999 AGGTCA gg AGTTCA 0 1 
MFAP1 AGGTCA gg AGTTCA 0 1 
BRWD1 AGGTCA gg AGTTCA 0 1 
C22orf30 AGGTCA gg AGTTCA 0 1 
CTTNBP2 AGGTCA gg AGTTCA 0 1 
THOC2 AGGTCA gg AGTTCA 0 1 
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Appendix B:  Perl Code for halfSiteMismatch  
#halfSiteMismatch 
#    VERSION: 1 (Dec. 2013) 
#    PURPOSE: Find the number of mismatch between twe half sites 
#    INPUT FILES:  halfSite1 sequence in .txt file,  
#                  halfSite2 sequence in .txt file 
#    OUTPUT FILES: Output to monitor and create .txt file 
###################### FILES ######################## 
 
my $file1 = 'patch1.txt';         #halfsite1 
my $file2 = 'patch2.txt';         #halfsite2 
my $mismatch = 'mismatchesInpatch.txt'; 
 
#################### VARIABLES ###################### 
 
my @halfsite1; 
my $halfsite1; 
my @halfsite2; 
my $halfsite2; 
my $symbol; 
my $mismatches; 
 
################### MAIN PROGRAM #################### 
 
open ONE, "<$file1" or die "Can't open $file1: $!\n"; 
open MIS, ">$mismatch" or die "Can't open $mismatch: $!\n"; 
 
my $line = <ONE>; 
   while (defined $line) { 
      chomp $line; 
      $halfsite1 .= uc($line); 
      push @halfsite1, $halfsite1; 
      $halfsite1 = ""; 
      $line = <ONE>; 
   } 
 
open TWO, "<$file2" or die "Can't open $file2: $!\n"; 
 
my $line = <TWO>; 
   while (defined $line) { 
      chomp $line; 
      $halfsite2 .= uc($line); 
      push @halfsite2, $halfsite2; 
      $halfsite2 = ""; 
      $line = <TWO>; 
   } 
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my $counter = 0; 
foreach $halfsite1 (@halfsite1){ 
        $halfsite2 = @halfsite2[$counter]; 
        print "Number of mismatches: "; 
        printf MIS "Number of mismatches:"; 
        for (my $i = 0, $mismatches = 0; $i < length(halfsite2); 
$i++) 
                { 
                $symbol = substr($halfsite1, $i, 1); 
                $con_symbol =  substr($halfsite2, $i, 1); 
                if ($symbol ne $con_symbol) 
                        { 
                        if ($symbol eq "-" || $con_symbol eq "-") 
                                { 
                                } 
                        else    { 
                                $mismatches++; 
                                } 
                        } 
                 } 
        print $mismatches, "\n"; 
        print MIS $mismatches, "\n"; 
        $counter++; 
} 
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Appendix C:  Perl Code for consensusMismatch  
 
#consensusMismatch 
#    VERSION: 1 (Dec. 2013) 
#    PURPOSE: Find the number of mismatch between consensus and 
result found 
#    INPUT FILES:  result seq .txt file 
#    OUTPUT FILES: Output to monitor and create .txt file 
###################### FILES ######################## 
 
my $file = 'mismatchesInPatch.txt'; #dr1D, dr2D, dr5D, dr1R, 
dr2R, dr5R, training 
my $mismatch = 'mismatchesInPatch.txt'; 
 
################### CONSTANTS ###################### 
 
my $consensus = "AGGTCA-----AGTTCA";     
# D strand , change number of "-" for spacing 
#my $consensus = "TGAACT-----TGACCT";    
# R strand 
 
#################### VARIABLES ###################### 
 
my @sequences; 
my $sequence; 
my $symbol; 
my $mismatches; 
 
################### MAIN PROGRAM #################### 
 
open SEQ, "<$file" or die "Can't open $file: $!\n"; 
open MIS, ">$mismatch" or die "Can't open $mismatch: $!\n"; 
 
my $line = <SEQ>; 
   while (defined $line) { 
      chomp $line; 
      $sequence .= uc($line); 
      push @sequences, $sequence; 
      $sequence = ""; 
      $line = <SEQ>; 
   } 
 
 
foreach $sequence (@sequences) 
        { 
        print "Mismatches in $sequence: "; 
        printf MIS "Mismatches in $sequence: "; 
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        for (my $i = 0, $mismatches = 0; $i < length($consensus); 
$i++) 
                { 
                $symbol = substr($sequence, $i, 1); 
                $con_symbol =  substr($consensus, $i, 1); 
                if ($symbol ne $con_symbol) 
                        { 
                        if ($symbol eq "-" || $con_symbol eq "-") 
                                { 
                                } 
                        else    { 
                                $mismatches++; 
                                } 
                        } 
                } 
        print $mismatches, "\n"; 
        print MIS $mismatches, "\n"; 
        } 
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Appendix D:  Perl Code for FindSeq  
 
# findSeq 
#    VERSION: 4 (Dec. 2013) 
#    PURPOSE: Find Possible retinoic acid binding site in given 
sequence 
#    INPUT FILES:  Sequence in FastA format 
#    OUTPUT FILES: Output to monitor and create .txt file 
############## LIBRARIES AND PRAGMAS ################ 
 
 use strict; 
 use warnings; 
 
#################### CONSTANTS ###################### 
 
 my $true = 1; 
 my $false = 0; 
 my $LF = "\n"; 
 my $pattern = 
"[agAG][gG][gtGT][tT][cC][aA].{1,2}[agAG][gG][gtGT][tT][cC][aA]";             
#based on my logo. DR1 and DR2.{1,2} DR5 .{5} 
#my $pattern = 
"[agAG][gG][gtGT][gtGT][gcGC][aA].{5}[agAG][gG][gtGT][gtGT][gcGC
][aA]";       
#based on papers 
 
#################### VARIABLES ###################### 
 
 my $header;         # Header of FastA-formatted input file 
 my $sequence;       # Sequence of input file 
 my ($G_percentage, 
     $C_percentage, 
     $A_percentage, 
     $T_percentage); # the nt distribution of the given sequence 
 my $freq;   # number of hit in the length of target  
                     # sequence by random chance using given  
                     # regular experssion 
 my @matches;        # Stores start and stop coordinate,  
                     # sequence of the match,  
                     # and the strain of the match 
 
###################### FILES ######################## 
 
 my $sequence_file = 'human_rai1_5000upstream.fasta'; 
 my $seq_hits = 'seqHit12.txt';  #naming: "seqHits" + number nt 
separeted 
 
    
 
63 
 
################### MAIN PROGRAM #################### 
  
open HITS, ">$seq_hits" or die "Can't open $seq_hits: $!\n"; 
 
#Get header and sequence from FastA-formatted file 
 ($header, $sequence) = get_genome_sequence($sequence_file); 
 
#Get and print the nucleotides distribution 
 ($G_percentage, $C_percentage, $A_percentage, $T_percentage) = 
get_nt_distribution($sequence); 
 
#calculate and print the frequence for the regular experssion 
 $freq  = ($G_percentage + $A_percentage) * $G_percentage * 
($G_percentage + $T_percentage) * $T_percentage * $C_percentage 
* $A_percentage * ($A_percentage + $G_percentage) * 
$G_percentage * ($G_percentage + $T_percentage) * $T_percentage 
* $C_percentage * $A_percentage +($C_percentage + $T_percentage) 
* $C_percentage * ($C_percentage + $A_percentage) * 
$A_percentage * $G_percentage * $T_percentage * ($T_percentage + 
$C_percentage) * $C_percentage * ($C_percentage + $A_percentage) 
* $A_percentage * $G_percentage * $T_percentage;                                                                                                    
#based on my logo, +strand + -strand 
 
#$freq  = ($G_percentage + $A_percentage) * $G_percentage * 
($G_percentage + $T_percentage) * ($G_percentage + $T_percentage) 
* ($G_percentage + $C_percentage) *$A_percentage * 
($G_percentage + $A_percentage) * $G_percentage * ($G_percentage 
+ $T_percentage) * ($G_percentage + $T_percentage) * 
($G_percentage + $C_percentage) * $A_percentage + 
($C_percentage + $T_percentage) * $C_percentage * ($C_percentage 
+ $A_percentage) * ($C_percentage + $A_percentage) * 
($C_percentage + $G_percentage) *$T_percentage * ($C_percentage 
+ $T_percentage) * $C_percentage * ($C_percentage + 
$A_percentage) * ($C_percentage + $A_percentage) * 
($G_percentage + $C_percentage) * $T_percentage;                                                                                                    
#based on papers, +strand + -strand 
 
 $freq =  $freq * length($sequence);   
# the finial number should *3(3 types of spacing) 
 
 print "Expect_number_of_hits_by_random_chance:", $freq , $LF; 
 printf HITS "Expect_number_of_hits_by_random_chance: $freq $LF"; 
 
#Find and print out all the matches 
 @matches = match_positions($pattern, $sequence); 
 if (@matches) { 
        print "Matches:", $LF; 
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        printf HITS "Matches: $LF"; 
        print "Start_Position End_Position Sequence Strain\n"; 
        printf HITS "Start_Position End_Position Sequence 
Strain\n"; 
        print_matches(@matches); 
 } 
 
 close HITS; 
 
#################### SUBROUTINES #################### 
 
#### GET_GENOME_SEQUENCE (file_path) 
#    Extracts header and sequence from given sequence file in 
FastA format 
#    Header has format >header information 
sub get_genome_sequence { 
 my ($file_path) = @_; 
 my $header;                  # header of FastA-formatted file 
 my $sequence;                # DNA sequence of file 
 my $line;                    # One line of input from file 
 
 open GENOME, "<$file_path" or die "Can't open $file_path: $!\n"; 
 $line = <GENOME>;            # Get first line (containing 
header) 
 ($header) = ($line =~ /^>(.*)/); 
 
 $line = <GENOME>; 
 while (defined $line) { 
        chomp $line;          # Remove line break 
        $sequence = $sequence . $line;     
                              # Append the line to the sequence 
        $line = <GENOME>;     # Read next line 
 } 
 
 return ($header, $sequence); 
} 
 
####GET_NT_DISTRIBUTION (sequence) 
#   find the nucleotides distributionof the given sequence 
sub get_nt_distribution { 
 my ($sequence) = @_; 
 my $len = length($sequence); 
 my ($num_G, $num_C, $num_A, $num_T, 
     $G_percentage, $C_percentage, $A_percentage, $T_percentage); 
 
 $num_G = $num_C = $num_A = $num_T = 0; 
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 print "length_of_the_sequence_is_$len. \n"; 
 for (my $i=0; $i<$len; $i++){ 
        my $char = substr($sequence, $i, 1); 
                if ($char eq "G" ||$char eq "g"){ 
                $num_G++;} 
                elsif ($char eq "C"||$char eq "c"){ 
                $num_C++;} 
         elsif ($char eq "A"||$char eq "a"){ 
                $num_A++;} 
         elsif ($char eq "T"||$char eq "t"){ 
                $num_T++;} 
                else{ 
                $num_G = $num_G; 
                $num_C = $num_C; 
         $num_A = $num_A; 
         $num_T = $num_T;} 
 } 
 
 $G_percentage = $num_G/$len; 
 $C_percentage = $num_C/$len; 
 $A_percentage = $num_A/$len; 
 $T_percentage = $num_T/$len; 
 
 print "G=", $G_percentage * 100, "%\n"; 
 print "C=", $C_percentage * 100, "%\n"; 
 print "A=", $A_percentage * 100, "%\n"; 
 print "T=", $T_percentage * 100, "%\n"; 
 
 return ($G_percentage, $C_percentage, $A_percentage, 
$T_percentage); 
} 
 
#### MATCH_POSITIONS (pattern, sequence) 
#    Finds all matches of pattern within seqeunce 
#    Searches direct strand and then other strand 
#    Returns start and end points of each match in an array, 
followed by 
#    "D" if found on direct strand or "R" if found on reverse 
strand 
#    Results are sorted by start points 
sub match_positions { 
 my $pattern;         # Given pattern 
 my $matched;         # matched pattern 
 my $sequence;        # given sequence, serves for both strands. 
 my $match_start;     # Starting coordinate of match 
 my $match_end;       # Ending coordinate of match 
 my @results;         # start coord..end coord for each match 
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 ($pattern, $sequence) = @_;     
                      # Extract parameters from list 
 
#Find matches in direct strand 
 while ($sequence =~ /($pattern)/g) { 
        my $matched = uc($1); 
        my $match_start = sprintf "%7d", pos($sequence) - 
length($&) + 1; 
        my $match_end = sprintf "%7d", pos($sequence); 
        push @results, "$match_start $match_end $matched +"; 
 } 
 
#Find matches in reverse strand 
 $sequence = Complement($sequence); 
 while ($sequence =~ /($pattern)/g) { 
        my $matched = uc($1); 
        my $match_start = sprintf "%7d", 
           length($sequence) - (pos($sequence) - length($&) + 1) 
+ 1; 
        my $match_end = sprintf "%7d", 
           length($sequence) - pos($sequence) + 1; 
        push @results, "$match_start $match_end $matched -"; 
 } 
 
 return sort(@results); 
} 
 
#### COMPLEMENT (sequence) 
#    Returns reverse complement of the given sequence 
sub Complement { 
 my ($sequence) = @_; 
 $sequence = reverse($sequence); 
 $sequence =~ tr/ACGTacgt/TGCAtgca/; 
 return $sequence; 
} 
 
#### PRINT_MATCHES 
#    Format array for printing 
#    Puts each element on separate line 
sub print_matches { 
 my (@matches) = @_; 
 foreach (@matches) { 
        print "$_\n"; 
        printf HITS "$_\n"; 
 } 
}  
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Appendix E:  Perl Code for FindMotif  
 
#findMotif 
#    VERSION: Version 6 (Dec. 2013) 
#    PURPOSE: Calculates position-specific scoring matrix  
#             from aligned sequence 
#             Finds sequences in genome sequence  
#             that PSSM fits best 
#    INPUT FILES:   
#      motif_input: input file of aligned motifs  
#                   alignments may have gaps, represented by "-" 
#      sequence_file: input file containing sequences in  
#                     FA format  
#                     may contain multiple contigs 
#    OUTPUT FILE: output file of best motifs within  
#                 sequence file 
#                 Each line is name of sequence, score, 
#                 start_coord, sequence 
 
############## LIBRARIES AND PRAGMAS ################ 
 
  use strict; 
 
#################### CONSTANTS ###################### 
 
  my $true = 1; 
  my $false = 0;            
  my $LF = "\n";            # Line feed 
  my $B = 0.01;             # Weighting factor for pseudocounts 
  my $threshold = -2**30;   # Save motifs with scores greater   
                            # than $threshold 
                            # Initialize to very small number  
                            # so that all scores initially  
                            # are saved 
  my $number_to_save = 100; # Number of top scores and  
                            # coordinates to save 
  my %bg_frequency =        # Nucleotide frequencies of overall  
                            # sequences 
     ("A" => 0.2146,        # Taken from target sequences 
      "T" => 0.2289, 
      "G" => 0.2891, 
      "C" => 0.2674);  
 
#################### VARIABLES ###################### 
 
  my $motif_length;     # Length of motifs 
  my @motif_sequences;  # All motifs read 
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  my @contigs;          # All contigs read 
  my $contig;           # Current contig 
  my $contig_index;     # Index of current contig 
  our @headers;         # All contig headers read 
  my %counts;           # {nucleotide}[position in motif] 
                        # Number of occurrences of  
                        # nucleotides at each position 
  my @informational;    # Those positions in the motif that        
                        # contribute to the motif  
                        # i.e. those that are not 
                        # don't-care positions. 
  my %log_q;            # $log_q{$nucleotide}[$position]  
                        # is the log of the frequency  
                        # of the nucleotide at that position 
  my %log_p;            # $log_p{$nucleotide} is the   
                        # background frequency of the nucleotide 
  my @hit_info;         # Information about each high-score seq 
 
###################### FILES ######################## 
#    Aligned sequences in the file defined by $motif_input are  
#    analyzed. 
#    The resulting PSSM is used to search through the file  
#    defined by $sequence_file. 
#    The sequence fragments within the large sequence that best  
#    match the PSSM 
#    are output to the file defined by $motif_hits 
 
  my $motif_input = 'DR2.txt';  
  #dr1, dr2, dr5, rDR1, rDR2, and rDR5 
  my $sequence_file = 'human_rai1_5000upstream.fasta'; 
  my $motif_hits = 'motifHits2D.txt';  
  #naming: "motifHits" + number nt separeted + direction 
 
################### MAIN PROGRAM #################### 
#    Read motifs 
#    Calculate PSSM 
#       Calculate counts of nucleotides in aligned motifs 
#       Determine informational columns 
#       Calculate frequencies (modified by pseudocounts) 
#    Read contigs (or single sequence) 
#    Use PSSM to score window running through contigs 
#    Print top hits 
 
  print "Getting motifs...", $LF; 
  @motif_sequences = Get_motif($motif_input); 
 
  print "Making PSSM...", $LF; 
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  Calc_nucleotide_counts (@motif_sequences); 
  @informational = Determine_informational_positions ( );  
  Calc_nucleotide_frequencies(@motif_sequences); 
  Calc_background_frequencies(); 
 
  print "Reading contigs...", $LF; 
  @contigs = Read_contigs($sequence_file); 
 
  print "Analyzing genome...", $LF; 
  foreach $contig_index (0 .. Size(@contigs)-1) { 
     Analyze_sequence($headers[$contig_index], 
$contigs[$contig_index]); 
  } 
 
  Print_hits(); 
 
#################### SUBROUTINES #################### 
 
#### INPUT/OUTPUT SUBROUTINES #### 
 
#### READ_CONTIGS 
#    Reads file of sequences in FastA format 
#    May be more than one sequence per file 
#    Saves header in global variable @header 
#    Returns array of sequences (all upper case) 
#    Saves total length of sequences read in global variable 
$total_length 
  sub Read_contigs { 
     my ($file_path) = @_; 
     open GENOME, "<$file_path" or die "Can't open $file_path: 
$!\n"; 
 
     our @headers;          # Stores FastA header in global  
                            # variable 
                            # Must be declared in main program  
                            # to be accessed 
     our $total_length = 0; # Stores number of nucleotides read  
                            # in global variable 
                            # Must be declared in main program  
                            # to be accessed 
     my $sequence;          # Individual sequence 
     my @sequences;         # Stores all sequences 
 
     my $line = <GENOME>; 
     while (defined $line) { 
        chomp $line; 
        if (substr($line,0,1) eq ">") {# Found header 
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           push @headers, $line;       # Save header 
           if (defined $sequence) {    # If sequence exists,  
                                       # save it 
              push @sequences, $sequence; 
              $total_length = $total_length + length($sequence); 
           } 
           $sequence = "";             # Initialize new sequence 
        } else {                       # More sequence 
               $sequence .= uc($line); # Append line to sequence 
        } 
        $line = <GENOME>; 
     } 
     push @sequences, $sequence;       # Save last sequence 
     return @sequences; 
  } 
 
#### GET_MOTIF 
#    Return array of aligned sequences  
#    Set the global variables $motif_length  
#    Quality check: All sequences must be the same length 
  sub Get_motif { 
     my ($motif_file_path) = @_; 
     my @motif_sequences; 
     my $line; 
     my $first_time = $true; 
     my $motif; 
     my $first_motif; 
   
     open MOTIF_INPUT, "<$motif_file_path" or die "Can't open 
$motif_file_path: $!\n"; 
   
     $line = <MOTIF_INPUT>;    
     while (defined $line) { 
        if ($line =~ /\b([ACGTacgt-]+)\b/) { 
           $motif = uc($1); 
           if ($first_time) { 
              $first_motif = $motif; 
              $motif_length = length($first_motif); 
              $first_time = $false; 
           } 
           if (length($motif) == $motif_length) { 
              push @motif_sequences, $motif; 
           } else { 
              die "Length of motif $motif in $motif_input is not 
$motif_length $LF"; 
           } 
        } 
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        $line = <MOTIF_INPUT>; 
     } 
     close MOTIF_INPUT; 
     return (@motif_sequences);   
  } 
 
#### PRINT_HITS 
#    Sort hits for final time 
#    Go through each hit from best to worst 
#    Formatted print of each hit to screen and to file 
  sub Print_hits { 
     sort_and_discard_excess_values(); 
     open HITS, ">$motif_hits" or die "Can't open $motif_hits: 
$!\n"; 
 
     foreach my $info (@hit_info) { 
        my ($score, $name, $start, $subregion) = @$info; 
        printf "%9s %6.1f %6d %s\n", $name, $score, $start, 
$subregion; 
        printf HITS "%9s %6.1f %6d %s\n", $name, $score, $start, 
$subregion; 
     } 
     close HITS  
  } 
       #### PSSM CONSTRUCTION SUBROUTINES #### 
 
#### CALC_NUCLEOTIDE_COUNTS (motif sequences) 
#    Accumulate nucleotide totals at each position 
#    counts{nucleotide}[position] is the number of times the 
nucleotide appears 
#          at the position 
  sub Calc_nucleotide_counts { 
     my (@motif_sequences) = @_; 
     my $motif; 
     my $position; 
     my $nucleotide; 
     my $count; 
     my $N = Size(@motif_sequences); 
 
     foreach $motif (@motif_sequences) { 
        foreach $position (0 .. $motif_length - 1) { 
           $nucleotide = substr($motif, $position, 1); 
           if (defined $counts{$nucleotide}[$position]) { 
              $counts{$nucleotide}[$position] = 
$counts{$nucleotide}[$position] + 1; 
           } else { 
              $counts{$nucleotide}[$position] = 1; 
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           } 
        } 
     } 
  } 
 
#### DETERMINE_INFORMATIONAL_POSITIONS 
#    At present, this subroutine does nothing useful: 
#       All positions are flagged as informational 
#    Informational positions of motif list are returned in array 
  sub Determine_informational_positions { 
     my @informational; 
#    @informational = (0, 1, 2, 3, 4, 5, 11, 12, 13, 14, 15, 16); 
#DR5 
    @informational = (0, 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 13); 
#DR2 
#    @informational = (0, 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12); 
#DR1 
 
     return @informational; 
  } 
 
#### CALC_NUCLEOTIDE_FREQUENCIES (motif sequences) 
#    Calculates the adjusted frequency at each position. 
#    
#    The actual frequency is 
#    
#               counts{nucleotide}[position] / N , 
#    where: 
#       counts{nucleotide}[position] is the number of times the  
#       nucleotide appearsat the position 
#       N is the number of motifs found in the training session, 
#    
#    The adjusted formula is a little more complicated: 
#    
#          counts{nucleotide}[position] + B * bg_pct[nucleotide] 
#    q{nucleotide}[position] = --------------------------------- 
#                                                   N + B 
#    where counts and N are as before, and: 
#    q{nucleotide}[position] is the adjusted frequency of the nt 
#    at the position 
#    B is the weighting constant for pseudocounts 
#    bg_pct[nucleotide] is the fraction that the nucleotide   
#    appears in total DNA 
#    We actually store $log_q{$nucleotide}[position], the log of  
#    the adjusted frequency, rather than the frequency itself. 
 
  sub Calc_nucleotide_frequencies { 
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     my (@motif_sequences) = @_; 
     my $motif; 
     my $position; 
     my $nucleotide; 
     my $count; 
     my $N = Size(@motif_sequences); 
 
     foreach $nucleotide ("A", "C", "G", "T") { 
        foreach $position (@informational) { 
           $count = ($counts{$nucleotide}[$position] or 0); 
           $log_q{$nucleotide}[$position] = 
              log(($count + $B * $bg_frequency{$nucleotide}) / 
($N + $B)); 
        } 
     } 
  } 
   
#### CALC_BACKGROUND_FREQUENCIES 
#    Calculate background percentage (for pseudocounts) 
  sub Calc_background_frequencies { 
     foreach my $nucleotide ("A", "C", "G", "T") { 
        $log_p{$nucleotide} = log($bg_frequency{$nucleotide}); 
     } 
  } 
     
#### SCORING SUBROUTINES #### 
#### ANALYZE_SEQUENCE 
#    Runs motif-sized window from beginning to end of  
#       sequence 
#    Scores each window 
#    If score exceeds threshold score, then store info 
  sub Analyze_sequence { 
     my ($name, $sequence) = @_; 
     my $region_start; 
     my $subregion; 
 
     foreach $region_start (0 .. length($sequence) - 
$motif_length) { 
        if ($region_start % 20000 == 0) {print $region_start, " 
"} 
        $subregion = substr($sequence, $region_start, 
$motif_length); 
        my $score = score_of_region($subregion);          
        if ($score > $threshold) { 
           store_hit_information($name, $score, $region_start, 
$subregion) 
        } 
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     } 
  } 
 
#### SCORE_OF_REGION 
#    The score is Sum [log_q - log_p] at each position 
#    This means that the closer the sequence is to the set that 
#       produced q, the higher the score 
#    If any region has a gap ("-") give it a lethal score 
  sub score_of_region { 
    my ($region) = @_; 
    my $score = 0; 
    foreach my $position (@informational) { 
       my $nucleotide = substr($region, $position, 1); 
       if ($nucleotide eq "-") {return $threshold - 1} 
       $score += $log_q{$nucleotide}[$position] - 
$log_p{$nucleotide}; 
    } 
    return $score 
  } 
 
#### STORE_HIT_INFORMATION (name, score, start, subregion) 
#    Store the hit information: 
#        Name of contig 
#        Score of window according to PSSM 
#        Start coordinate of window within contig 
#        Sequence of window 
#    If we've accumulated too many hits, then discard all but  
#        the highest-scoring ones. 
#    Also reset the threshold to the worst score saved 
 
  sub store_hit_information { 
     my ($name, $score, $start, $subregion) = @_; 
 
     push @hit_info, [$score, $name, $start, $subregion]; 
     if (Size(@hit_info) > 9 * $number_to_save) {  
        sort_and_discard_excess_values();  
        $threshold = $hit_info[-1][0]; 
     } 
  } 
 
#### SORT_AND_DISCARD_EXCESS_VALUES 
#    Sort saved scores highest to lowest 
#    Reset last index of hit_info so that only number_to_save 
are retained 
  sub sort_and_discard_excess_values { 
     @hit_info = reverse sort { $$a[0] <=> $$b[0] } @hit_info; 
    
 
75 
 
     $#hit_info = $number_to_save - 1 if @hit_info > 
$number_to_save; 
  } 
 
 #### MISCELLANEOUS SUBROUTINES #### 
##### SIZE (array) 
#     Returns size of array  
#     Synonym for scalar (array) 
  sub Size {return scalar(@_)} 
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Appendix F:  Perl Code for reverseMotif 
 
#reverseMotif 
#    VERSION: Version 2 (Dec. 2013) 
#    PURPOSE: reture the reverse complement of given sequence 
#    INPUT FILES: 
#             motif_input: .txt sequence file 
#    OUTPUT FILE: 
#             rev_motif: .txt sequence file 
############## LIBRARIES AND PRAGMAS ################ 
 
  use strict; 
 
###################### FILES ############################ 
 
  my $motif_input = 'dr1.txt';   #dr1, dr2, and dr5 
  my $rev_motif = 'rDR1.txt';    #rDR1, rDR2, and rDR5 
 
#################### CONSTANTS ###################### 
 
  my $true = 1; 
  my $false = 0; 
  my $LF = "\n";                 # Line feed 
 
################### MAIN PROGRAM ######################## 
 
  my @motif_sequences; 
  my $line; 
  my $first_time = $true; 
  my $motif; 
  my $first_motif; 
  my $motif_length; 
 
  open MOTIF_INPUT, "<$motif_input" or die "Can't open 
$motif_input: $!\n"; 
  open NEW, ">$rev_motif" or die "Can't open $rev_motif: $!\n"; 
 
  $line = <MOTIF_INPUT>; 
  while (defined $line) { 
        if ($line =~ /\b([ACGTacgt-]+)\b/) { 
           $motif = reverse($1); 
    $motif =~ tr/ACGTacgt-/TGCAtgca-/; 
           if ($first_time) { 
              $first_motif = $motif; 
              $motif_length = length($first_motif); 
              $first_time = $false; 
           } 
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           if (length($motif) == $motif_length) { 
              push @motif_sequences, $motif; 
           } else { 
              die "Length of motif $motif in $motif_input is not 
$motif_length $LF"; 
           } 
        } 
  $line = <MOTIF_INPUT>; 
  } 
 
  foreach (@motif_sequences){ 
       printf NEW "$_\n"; 
 print "$_\n"; 
  } 
 
  close $rev_motif; 
  close MOTIF_INPUT 
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Appendix G:  Patch search raw result 
 
StartPos. 
Dis. 
(kb) Str. halfSite1   halfSite2 
within  
DHSs 
consensus 
Mismatch 
halfSites 
Mismatch 
chr17: 17581163 -3.624 + AGGTCA ----- GGGTCA 
 
2 1 
chr17: 17581174 -3.613 - TGACCC ----- TGACCT 
 
2 1 
chr17: 17582877 -1.91 - TGACCT - AGGTGA 
 
6 5 
chr17: 17583524 -1.263 + TGCCCT ----- AGGACA 
 
6 4 
chr17: 17587925 3.138 - TTACCT -- AGGGAG 
 
7 6 
chr17: 17589242 4.455 - AGGGAG -- AGGTGA + 5 3 
chr17: 17592499 7.712 + TGACCT - AGGTGA 
 
6 5 
chr17: 17592534 7.747 - TGCACT ----- AGGCTG 
 
5 5 
chr17: 17599286 14.499 - GGGTGA -- AGGGAG + 6 4 
chr17: 17599890 15.103 + GGGTGA ----- TGGACT 
 
6 4 
chr17: 17601915 17.128 - TGACCC -- AGGCTG + 6 4 
chr17: 17602191 17.404 + TGCCCT -- AGGGAG + 7 5 
chr17: 17604612 19.825 + TGCACT -- TGCCCT + 2 1 
chr17: 17606566 21.779 + GGGTCA -- AGGACA + 3 2 
chr17: 17606629 21.842 + TGCACT -- AAGTCA + 6 5 
chr17: 17608729 23.942 - TGACCT - AGGTGA 
 
6 5 
chr17: 17610723 25.936 + AGGTGA - AGGTGA 
 
3 0 
chr17: 17612536 27.749 + AGGCTG -- AGGCTG 
 
7 0 
chr17: 17614711 29.924 + TGCCCT - TCCCCC 
 
5 2 
chr17: 17618419 33.632 + TGCACT -- GGGTGA 
 
6 5 
chr17: 17620363 35.576 - TGGACT -- TGACCT 
 
1 2 
chr17: 17620761 35.974 - TGCCCT -- TCACCC 
 
4 3 
chr17: 17622912 38.125 - TTACCT - AGGTGA 
 
7 6 
chr17: 17624222 39.435 + AGGGAG ----- AGGGAG 
 
7 0 
chr17: 17627149 42.362 + TTACCT -- TGACCC + 3 2 
    
 
79 
 
chr17: 17628863 44.076 - TGACCC ----- TCCCCC + 5 2 
chr17: 17629651 44.864 + GGGTGT - TGACCC + 5 5 
chr17: 17636358 51.571 - TGCCCT -- GGGTGT + 6 4 
chr17: 17640554 55.767 - AGGCTG ----- TGACCC + 6 4 
chr17: 17641675 56.888 + GGTTCA ----- GGGTGA + 5 2 
chr17: 17643193 58.406 - AGGTGA -- AGGTCA + 2 1 
chr17: 17644246 59.459 + TGCCCT ----- AGGGAG + 7 5 
chr17: 17644692 59.905 - AGGGAG -- TCCCCC + 8 6 
chr17: 17648939 64.152 + TGACCT - AGGTGA 
 
6 5 
chr17: 17649588 64.801 + AGGGAG -- AGGGAG + 7 0 
chr17: 17656406 71.619 - TGACCC -- TGCCCT + 3 2 
chr17: 17659738 74.951 + TGACCT - AGGTGA 
 
6 5 
chr17: 17660181 75.394 + GTTCAC -- GGGTGA 
 
9 5 
chr17: 17663913 79.126 + AAGTCA -- GGGTGT + 5 4 
chr17: 17665427 80.64 + TGGACT - TGCCCT + 2 2 
chr17: 17671008 86.221 - AGGGAG ----- TGACCC + 6 5 
chr17: 17672087 87.3 - TCCCCC ----- TGCACT + 6 3 
chr17: 17677608 92.821 - AGGTGA - TCACCC + 6 6 
chr17: 17677615 92.828 - TGACCT - AGGTGA + 6 5 
chr17: 17680497 95.71 - TGCCCT - TAACCT 
 
3 2 
chr17: 17683931 99.144 + AGGTGA -- TCACCT 
 
6 6 
chr17: 17683939 99.152 - AGGTGA -- TCACCT 
 
6 6 
chr17: 17684302 99.515 - AGGGGA -- GGGTGA + 5 2 
chr17: 17684915 100.128 + GGGTGA ----- AGGGAG + 6 4 
chr17: 17685338 100.551 + GGGAGA - AGGGAG + 7 4 
chr17: 17686631 101.844 + TGACCT ----- GGGTCA + 5 4 
chr17: 17686642 101.855 - TGACCC ----- AGGTCA + 5 4 
chr17: 17687847 103.06 + GGGAGA -- TGACCT + 4 5 
chr17: 17688312 103.525 - GGGAGA -- AGGTGA + 5 2 
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chr17: 17692051 107.264 - GGGAGA - AGGGAG 
 
7 4 
chr17: 17692078 107.291 - GGGAGA - AGGGAG 
 
7 4 
chr17: 17692480 107.693 + AGGACA - GGGTGT 
 
5 4 
chr17: 17692590 107.803 - AGGACA -- TGCCCT 
 
4 4 
chr17: 17693114 108.327 + GAGGCA ----- GGGAGA 
 
7 3 
chr17: 17693226 108.439 - AGGGGA -- AGGGAG 
 
6 2 
chr17: 17693313 108.526 + GGTTCA - AGGTCA 
 
3 2 
chr17: 17693320 108.533 - TGACCT - TGAACC 
 
3 2 
chr17: 17694566 109.779 + TGCCCT ----- TGCCCT 
 
3 0 
chr17: 17694900 110.113 - AGGGGA - AGGGGA 
 
5 0 
chr17: 17695790 111.003 + AGGGGA -- AGGGAG + 6 2 
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Appendix H:  oldFindSeq Search Raw Result 
Expect_number_of_hits_by_random_chance: 12.9962498935582 
Matches: 
StartPos. 
Dis.  
(kb) Str. halfSite1   halfSite2 
within  
DHSs 
consensus 
Mismatch 
halfSites 
Mismatch 
chr17: 17581163 -3624 + AGGTCA ccaag GGGTCA 
 
2 1 
chr17: 17582877 -1910 + AGGTCA gg AGTTCA 
 
0 1 
chr17: 17583517 -1270 - TCCCCT c TGCCCT 
 
4 1 
chr17: 17589217 4430 - TCCACC tggga TGCCCC 
 
5 2 
chr17: 17589507 4720 + GGTGGA ga GGGTGA 
 
7 2 
chr17: 17589979 5192 + GGTGGA gtggg GGTGGA 
 
7 0 
chr17: 17590664 5877 + GGGGGA ag AGTGGA 
 
5 2 
chr17: 17596741 11954 - TCCCCT ccccg TGCCCC + 5 2 
chr17: 17600371 15584 - TGCCCT tgccc TGACCT + 2 1 
chr17: 17603124 18337 - TCCCCC accac TCCACC + 8 1 
chr17: 17604612 19825 - TGCACT gc TGCCCT + 2 1 
chr17: 17604862 20075 - TCCCCT ttccc TCCCCT + 5 0 
chr17: 17608667 23880 + GGTGCA gt GGGTCA 
 
5 2 
chr17: 17609703 24916 + AGGGCA tgcat AGGTGA 
 
3 2 
chr17: 17610723 25936 + AGGTGA c AGGTGA 
 
3 0 
chr17: 17614711 29924 - TGCCCT g TCCCCC 
 
5 2 
chr17: 17615674 30887 + GGTGGA a GGGGCA 
 
7 2 
chr17: 17618427 33640 + GGGTGA gc AGGGGA 
 
5 2 
chr17: 17620753 35966 + GGGTGA gc AGGGCA 
 
4 3 
chr17: 17621440 36653 - TCCCCT c TCCCCC 
 
6 1 
chr17: 17627776 42989 - TCCCCC c TCCCCT + 6 1 
chr17: 17628852 44065 + GGGGGA ccacc GGGTCA + 5 2 
chr17: 17628929 44142 + AGGGGA ga GGTGGA + 5 2 
chr17: 17629039 44252 - TGCCCC c TCCCCT + 5 2 
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chr17: 17629149 44362 + GGGGGA g AGGGGA + 6 1 
chr17: 17631247 46460 - TGCCCC c TCCCCT 
 
5 2 
chr17: 17641675 56888 + GGTTCA gggct GGGTGA + 5 2 
chr17: 17641841 57054 + GGGTGA aggcg GGGGCA + 5 2 
chr17: 17642972 58185 - TGACCT ctggc TGCCCC + 3 2 
chr17: 17643185 58398 - TGACCT tg TCACCT + 2 1 
chr17: 17648079 63292 + GGGTGA ca GGTTGA 
 
4 1 
chr17: 17654082 69295 - TCACCC ctgac TCCACC 
 
7 2 
chr17: 17656398 71611 + AGGGCA ct GGGTCA + 3 2 
chr17: 17658101 73314 + AGGGCA ag GGTGCA 
 
3 2 
chr17: 17660820 76033 - TCCACC t TCCCCC 
 
6 1 
chr17: 17664823 80036 + GGGGGA t GGTGGA + 6 1 
chr17: 17665765 80978 + GGTTCA aattt AGTTGA 
 
3 2 
chr17: 17666024 81237 + GGGGCA ggtag AGGTGA + 4 3 
chr17: 17672076 87289 + AGTGCA tggga GGGGGA + 6 3 
chr17: 17675694 90907 - TCCCCT c TCACCC 
 
5 2 
chr17: 17676316 91529 + AGTGGA tg GGTGGA 
 
6 1 
chr17: 17679489 94702 + GGGGGA aactg AGGTCA 
 
4 3 
chr17: 17684294 99507 - TCACCC cc TCCCCT + 5 2 
chr17: 17686510 101723 + GGGGGA cc GGGGCA + 6 1 
chr17: 17686901 102114 - TCCCCC tc TGCCCC + 6 1 
chr17: 17693313 108526 + GGTTCA a AGGTCA 
 
3 2 
chr17: 17694566 109779 - TGCCCT gggct TGCCCT 
 
3 0 
chr17: 17694778 109991 - TGCCCC tc TCCCCC 
 
6 1 
chr17: 17694893 110106 - TCCCCT a TCCCCT 
 
5 0 
chr17: 17695284 110497 - TGCCCC agccc TCACCT + 4 3 
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Appendix I:  FindMotif Search Raw Result 
 
DR5 Hits 
StartPos. 
Dis. 
(kb) Str. 
score  
(LN 
scale) halfSite1   halfSite2 
within  
DHSs 
consensus 
Mismatch 
halfSites 
Mismatch 
Chr17: 17581163 -3.624 + 11 AGGTCA ccaag GGGTCA 
 
2 1 
Chr17: 17665765 80.978 + 8.9 GGTTCA aattt AGTTGA 
 
3 2 
Chr17: 17656958 72.171 + 6.5 AGGCCA ccctc AAATCA 
 
3 3 
Chr17: 17665647 80.86 + 5.3 GGGTCA ggggc ATGGCA + 4 3 
Chr17: 17616614 31.827 + 5.2 AGTTCA agact AGAGCC 
 
4 3 
Chr17: 17672555 87.768 + 5.1 GGGTCA ccctc AGGGCT + 4 3 
Chr17: 17679350 94.563 + 4.3 AATTCA ggttt GGTTCT 
 
4 3 
Chr17: 17631805 47.018 + 4.2 GGTCCA atggc AGGGCA 
 
5 3 
Chr17: 17641675 56.888 + 3.9 GGTTCA gggct GGGTGA + 5 2 
Chr17: 17609818 25.031 + 3.3 GGGCCA gggaa AGCCCA 
 
4 2 
Chr17: 17669339 84.552 + 3.3 GGTCCA ggcct GGTTCC + 5 2 
Chr17: 17694487 109.7 + 3.3 GGGCCA gggca AGCTGA 
 
4 4 
Chr17: 17647711 62.924 + 3.1 GGTTCA cagaa ATAGCA 
 
5 4 
Chr17: 17672775 87.988 + 3.1 AGGTCA gggct GGAGGA 
 
4 4 
Chr17: 17587716 2.929 + 2.9 AATCCA ctgat GGGTCA 
 
5 4 
Chr17: 17594963 10.176 + 2.8 AAGTCA gaaaa AGGCCT 
 
4 3 
Chr17: 17621328 36.541 + 2.8 AGATCA aaggt CGTTCA 
 
2 2 
Chr17: 17681096 96.309 + 2.8 AAGTGA ttgca AGTTCA 
 
2 3 
Chr17: 17591560 6.773 + 2.7 AGGCCA aggcg GGTGGA 
 
4 4 
Chr17: 17592674 7.887 + 2.4 AGGTCA aggca GATGGA 
 
4 5 
Chr17: 17616671 31.884 + 2.4 AGGCCA gctgc AGTGGC 
 
4 4 
Chr17: 17670553 85.766 + 2.2 AGGCCA cagca GGCCCA + 4 2 
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Chr17: 17640323 55.536 + 2.1 AGACCA ctggc ATTTCT + 4 4 
Chr17: 17660431 75.644 + 2 GGTCCA gggag AGCTCT 
 
5 4 
Chr17: 17660724 75.937 + 2 AGACCA gttca ATTCCA 
 
4 2 
Chr17: 17595366 10.579 + 1.9 AAATCA gactt AATTGA 
 
4 2 
Chr17: 17647276 62.489 + 1.9 AGACCA gcagg AGCTCT 
 
4 3 
Chr17: 17670766 85.979 + 1.6 AAGTCA gctcc AGCCCC + 4 4 
Chr17: 17680856 96.069 + 1.6 AGGTCA gaagt GGCTGT 
 
4 4 
Chr17: 17653487 68.7 + 1.4 AGTCCA gctgt GGCTCC + 5 4 
Chr17: 17676911 92.124 + 1.4 GGATCA aaaca ATGTGA 
 
5 4 
Chr17: 17643351 58.564 + 1.3 AGGCCA ggctg AGCCCT + 4 2 
Chr17: 17641079 56.292 + 1.2 GGCTCA gcctg ATTTCA 
 
3 3 
Chr17: 17592601 7.814 + 1.1 AGGTCA catct AACCCT 
 
4 4 
Chr17: 17609664 24.877 + 1 GGGTCA tgggg TGTGCA 
 
3 3 
Chr17: 17612860 28.073 + 1 GGGGCA tttgc AGTTCC 
 
3 4 
Chr17: 17632678 47.891 + 1 GGTTCA caagc GTGGCA 
 
6 3 
Chr17: 17665776 80.989 + 1 AGTTGA gggaa AGTTCT 
 
3 2 
Chr17: 17600371 15.584 - 10.7 TGCCCT tgccc TGACCT + 2 1 
Chr17: 17614674 29.887 - 7.8 GGCACT gagtg TGACCC 
 
3 4 
Chr17: 17623236 38.449 - 7.2 TGGCCC acatc TGACCT 
 
3 2 
Chr17: 17619071 34.284 - 6.9 TGGACT cattc TGGCCC 
 
3 2 
Chr17: 17692584 107.797 - 6.3 GGCACT tgtcc TGAACC 
 
4 3 
Chr17: 17638999 54.212 - 6.1 TGATTT agaag TGGCCT 
 
3 3 
Chr17: 17622073 37.286 - 5.9 TGACCC cctgc TGACTC 
 
4 1 
Chr17: 17641428 56.641 - 5.7 AGCACT cagta TGGCCT 
 
3 3 
Chr17: 17693991 109.204 - 5.7 GGAAAT gagag TGATCT 
 
3 3 
Chr17: 17639685 54.898 - 5.4 AGCACT gctct TGACTT + 3 4 
Chr17: 17615304 30.517 - 4.7 GGATTT ttatg TGAACT 
 
4 3 
Chr17: 17657342 72.555 - 4.5 TGACAC tcacc TGAACC 
 
5 2 
Chr17: 17580396 -4.391 - 4.3 TGCCCC aacac TGACTT 
 
4 3 
    
 
85 
 
Chr17: 17639405 54.618 - 4.1 TGCATT gcgca TGGCCC 
 
4 4 
Chr17: 17656218 71.431 - 4.1 GGCCCT gtctg TGGCCT + 4 2 
Chr17: 17665273 80.486 - 4 GGACTT ttggt TGAACC + 5 4 
Chr17: 17688476 103.689 - 3.9 TGCTCC acagg TGAACC 
 
5 2 
Chr17: 17621235 36.448 - 3.5 TGAAGC tgcac TGACCT 
 
2 3 
Chr17: 17589278 4.491 - 3.3 TCCTCC tcctc TGACCT + 4 4 
Chr17: 17679910 95.123 - 3.2 TCATCC cacct TGGCCT 
 
4 4 
Chr17: 17690568 105.781 - 3 TGGCAT cagcc TGGCCT 
 
4 1 
Chr17: 17607579 22.792 - 2.9 TGCACA aggtg TGACCT 
 
2 3 
Chr17: 17648952 64.165 - 2.9 TCCACC cgcct TGGCCT 
 
4 4 
Chr17: 17683620 98.833 - 2.9 TCCACC cacct TGGCCT 
 
4 4 
Chr17: 17646544 61.757 - 2.7 TCCTCT tgcct TGGCCT 
 
4 3 
Chr17: 17684812 100.025 - 2.7 TGAACT tcctg CGGCCT + 2 3 
Chr17: 17604278 19.491 - 2.4 TGACCT cgcag AGACCC + 3 2 
Chr17: 17642972 58.185 - 2.4 TGACCT ctggc TGCCCC + 3 2 
Chr17: 17674439 89.652 - 2.2 GGCCAT gcccc TGACCC 
 
5 4 
Chr17: 17639221 54.434 - 2 TCCCCT gaact TGGCCC 
 
5 3 
Chr17: 17622442 37.655 - 1.9 TGCTCC tgccc TGGCCC 
 
5 2 
Chr17: 17633630 48.843 - 1.8 TGATCA gaaga TGAACT + 3 2 
Chr17: 17612939 28.152 - 1.4 TGGCCT cattc TGGTCC 
 
5 2 
Chr17: 17641439 56.652 - 1.3 TGGCCT gagta TGGCTC 
 
5 2 
Chr17: 17695177 110.39 - 1.3 GGGTCC tttcc TGACCC 
 
5 3 
Chr17: 17595385 10.598 - 1.2 GGCTCT cttct TGACTC 
 
5 5 
Chr17: 17655355 70.568 - 1.2 TGAAGT atgag TGAATT + 3 1 
Chr17: 17636801 52.014 - 1.1 AGGCAT tcaga TGACCC + 5 4 
Chr17: 17645855 61.068 - 1 AGCTCT ggcac TGAATT + 5 4 
Chr17: 17685833 101.046 - 1 GCATCT ggcag TGGCCC + 5 5 
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DR2 Hits 
StartPos. 
Dis. 
(kb) Str. 
score  
(LN 
scale) halfSite1   halfSite2 
within  
DHSs 
consensus 
Mismatch 
halfSites 
Mismatch 
Chr17: 17582877 -1.91 + 16 AGGTCA gg AGTTCA 
 
0 1 
Chr17: 17620355 35.568 + 12.1 AGGTCA ga AGTCCA 
 
1 2 
Chr17: 17609115 24.328 + 10.6 AGATCA cg AGGTCA 
 
2 1 
Chr17: 17647882 63.095 + 10.6 AGATCA cg AGGTCA 
 
2 1 
Chr17: 17584029 -0.758 + 9.3 AGGCCA gg AATTCA 
 
2 3 
Chr17: 17633904 49.117 + 7.7 GGGCCA ct AGTGCA 
 
3 3 
Chr17: 17649817 65.03 + 7.6 AGTTCA gg AGCTCC + 3 2 
Chr17: 17581174 -3.613 + 6.6 GGGTCA ca AGCTGA 
 
3 3 
Chr17: 17624135 39.348 + 6.3 AGGTCA gg GTTTCC 
 
3 4 
Chr17: 17591584 6.797 + 6.1 AGGTCA gg AGTTCG 
 
1 2 
Chr17: 17647890 63.103 + 6.1 AGGTCA gg AGTTCG 
 
1 2 
Chr17: 17658318 73.531 + 6 AGGTCA gg AGAGGA 
 
3 3 
Chr17: 17599997 15.21 + 5.9 GGGTCA gg GGGTCC 
 
4 1 
Chr17: 17691951 107.164 + 5.8 AGGTCA ta AAACCA 
 
3 3 
Chr17: 17680856 96.069 + 5.6 AGGTCA ga AGTGGC 
 
3 4 
Chr17: 17603299 18.512 + 4.7 GGATCA ca AGAGCA + 4 2 
Chr17: 17610409 25.622 + 4.7 AGTTCA gg AGTTCG 
 
2 1 
Chr17: 17609471 24.684 + 4.6 AGGTCA gc AGCCCT 
 
3 3 
Chr17: 17695091 110.304 + 4.3 AGGCCA gc GAGTCA 
 
4 3 
Chr17: 17641456 56.669 + 3.9 AGGCCA gt ATGGCA 
 
4 2 
Chr17: 17657050 72.263 + 3.9 AGTCCA tc ATTTGA 
 
4 3 
Chr17: 17616606 31.819 + 3.3 AGCCCA gg AGTTCA 
 
2 2 
Chr17: 17616739 31.952 + 3.2 AGGTCA gg GGTTCG 
 
2 3 
Chr17: 17581095 -3.692 + 3.1 AGGTCA ag GGAGGA 
 
4 4 
Chr17: 17598927 14.14 + 2.8 GGTTCC ca AGTTCA 
 
3 2 
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Chr17: 17617288 32.501 + 2.8 AAGTCA ca GGACCA + 4 4 
Chr17: 17628855 44.068 + 2.7 GGACCA cc GGGTCA + 5 2 
Chr17: 17641393 56.606 + 2.7 GGGTCA ag GGGGCC 
 
5 2 
Chr17: 17649367 64.58 + 2.7 AGGCCA cc ATTGCC + 4 4 
Chr17: 17645963 61.176 + 2.5 AAGTCG ca AGTTCA + 2 3 
Chr17: 17601150 16.363 + 2.3 AGGTCA ca CGTTCT + 2 3 
Chr17: 17606566 21.779 + 2.3 GGGTCA gg AGGACA + 3 2 
Chr17: 17662637 77.85 + 2.3 AGGACA ca AGTTGA + 2 3 
Chr17: 17636206 51.419 + 2.2 AGGCCA ga GGTTGT + 4 5 
Chr17: 17641402 56.615 + 2.1 GGGCCA gt ATGGCA 
 
5 3 
Chr17: 17662256 77.469 + 2.1 GGGTCA ga GGGTGC 
 
5 2 
Chr17: 17648152 63.365 + 1.8 AGGTCA ga GTTCCT 
 
4 5 
Chr17: 17690105 105.318 + 1.8 AGGCCA gg AGTGGT 
 
4 4 
Chr17: 17609664 24.877 + 1.5 GGGTCA tg GGGTGT 
 
5 2 
Chr17: 17654257 69.47 + 1.4 ACTTCA tc ATTTCA + 3 1 
Chr17: 17656398 71.611 + 1.2 AGGGCA ct GGGTCA + 3 2 
Chr17: 17665083 80.296 + 1.1 AGGCCA ag GAGGCA + 5 3 
Chr17: 17644738 59.951 + 1 TGTTCA tg AGTTCT + 3 2 
Chr17: 17662582 77.795 + 1 AGGTCA ga GTGGCC + 5 4 
Chr17: 17690637 105.85 + 1 GGGCCA cc AGACCC 
 
5 3 
Chr17: 17667997 83.21 - 12.6 TGAACT cc TGGCCT 
 
1 2 
Chr17: 17668123 83.336 - 12.6 TGAACT cc TGGCCT 
 
1 2 
Chr17: 17681654 96.867 - 10.9 TGAACT gg TGGCCC 
 
2 3 
Chr17: 17659730 74.943 - 10.7 GGACCT cc TGACCT 
 
2 1 
Chr17: 17592141 7.354 - 8.8 TGACCT ca TGATCC 
 
3 2 
Chr17: 17683318 98.531 - 8.8 TGACCT ca TGATCC 
 
3 2 
Chr17: 17684858 100.071 - 8.8 TGAGCT gc TGGCCT + 2 2 
Chr17: 17675681 90.894 - 6.6 TGGCCT cc TGGCCT 
 
3 0 
Chr17: 17691986 107.199 - 6.6 GGAACC ag TGGCCT 
 
3 4 
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Chr17: 17692211 107.424 - 6.3 AGGCCT ag TGACCT 
 
3 2 
Chr17: 17638587 53.8 - 6.1 TGAACT cc TGTCCT 
 
1 2 
Chr17: 17650168 65.381 - 6.1 TGAACT cc CGACCT 
 
1 2 
Chr17: 17674638 89.851 - 6 TGAGCC cc TGGCCT 
 
3 3 
Chr17: 17590685 5.898 - 5.9 TGCACT ga TGGTCT 
 
3 2 
Chr17: 17671094 86.307 - 5.8 TGCAAT gg TGGCCT + 3 3 
Chr17: 17592807 8.02 - 5.4 GCAACT tg TGACTT 
 
3 4 
Chr17: 17628673 43.886 - 5.3 TGCTCC gg TGACCC + 4 2 
Chr17: 17624068 39.281 - 4.9 TCAGAT cc TGACCT 
 
3 3 
Chr17: 17629458 44.671 - 4.9 TGGCCT tg TGGCCC + 4 1 
Chr17: 17599893 15.106 - 4.6 TGATTT gt TGGACT 
 
4 3 
Chr17: 17643185 58.398 - 4.3 TGACCT tg TCACCT + 2 1 
Chr17: 17624508 39.721 - 4 GGAACT gt TGGCTC + 4 5 
Chr17: 17593343 8.556 - 3.8 GGCCTT at TGACCT 
 
4 3 
Chr17: 17589281 4.494 - 3.3 TCCTCC tc TGACCT + 4 4 
Chr17: 17593164 8.377 - 3.3 GGATCT ca TGGACC 
 
5 4 
Chr17: 17683310 98.523 - 3.2 CGATCT cc TGACCT 
 
2 2 
Chr17: 17628343 43.556 - 3.1 GGGGCT gc TGACCC + 4 4 
Chr17: 17600898 16.111 - 3 TGCTCT tg TGGTCT + 4 1 
Chr17: 17654404 69.617 - 3 TGGCAT gt TGGCCT 
 
4 1 
Chr17: 17604612 19.825 - 2.8 TGCACT gc TGCCCT + 2 1 
Chr17: 17671442 86.655 - 2.8 TTAAAT ca TGACCT 
 
2 3 
Chr17: 17581309 -3.478 - 2.7 TGACCT cc AGAACT 
 
3 2 
Chr17: 17627149 42.362 - 2.7 TTACCT cc TGACCC + 3 2 
Chr17: 17633259 48.472 - 2.6 AGATTT gc TGAACC + 5 4 
Chr17: 17613918 29.131 - 2.5 GGCACT gg TGGCTT 
 
4 4 
Chr17: 17613903 29.116 - 2.4 GGCCCT gc TGGCCC 
 
5 3 
Chr17: 17646305 61.518 - 2.4 TGATTT at TGATTT 
 
4 0 
Chr17: 17581301 -3.486 - 2.3 TGGAGT tc TGACCT 
 
2 3 
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Chr17: 17692793 108.006 - 2.3 AGAGCC gc TGGCCT 
 
4 4 
Chr17: 17670211 85.424 - 2 TGGTCT tg TGGCTT + 4 2 
Chr17: 17580903 -3.884 - 1.9 TGGATC ag TGACTT 
 
4 3 
Chr17: 17694800 110.013 - 1.7 TCCCTT cc TGACCC 
 
5 4 
Chr17: 17610169 25.382 - 1.6 TGGAAT gc TGGTCT 
 
4 2 
Chr17: 17670693 85.906 - 1.6 AGAGCT gt TGGTCT + 4 3 
Chr17: 17663809 79.022 - 1.4 TCAGTT ag TGGCCT + 4 4 
Chr17: 17620556 35.769 - 1.3 TGGCTT cc TGGCCC 
 
5 2 
Chr17: 17589544 4.757 - 1.2 GGCCCC tt TGATCT 
 
5 4 
Chr17: 17610294 25.507 - 1.2 TGCCCT gg TGAGCT 
 
3 2 
Chr17: 17671275 86.488 - 1.2 TGCCTC tc TGAACC 
 
6 3 
Chr17: 17624800 40.013 - 1.1 TGAATT ca GGAACT 
 
3 2 
Chr17: 17639584 54.797 - 1 TCCTCT ca TGGCCC   5 4 
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DR1 Hits 
StartPos. 
Dis. 
(kb) Str. 
score  
(LN 
scale) halfSite1   halfSite2 
within  
DHSs 
consensus 
Mismatch 
halfSites 
Mismatch 
Chr17: 17648152 63.365 + 12.7 AGGTCA g AGTTCC 
 
1 2 
Chr17: 17693313 108.526 + 10.7 GGTTCA a AGGTCA 
 
3 2 
Chr17: 17640543 55.756 + 10.4 GGGTCA t AGCTCA + 2 2 
Chr17: 17606922 22.135 + 9.9 AGGTCA c AGAGCA 
 
2 2 
Chr17: 17603225 18.438 + 9 GGTTCA a AGCTCA + 3 2 
Chr17: 17588663 3.876 + 8.4 AGGTCA c AGCCCA 
 
2 2 
Chr17: 17615796 31.009 + 7.2 AGGTCA a ATGGCA 
 
3 2 
Chr17: 17620355 35.568 + 7.2 AGGTCA g AAGTCC 
 
3 2 
Chr17: 17673902 89.115 + 7.1 AGGTCA g GGGCCA + 3 2 
Chr17: 17635730 50.943 + 5.9 GGATCA g GGGTCA 
 
4 1 
Chr17: 17620429 35.642 + 5.7 GGGTCA a GAGTCA 
 
4 1 
Chr17: 17662582 77.795 + 5.6 AGGTCA g AGTGGC + 3 4 
Chr17: 17666307 81.52 + 5.2 AGGCCA g AGCTGA + 3 3 
Chr17: 17654242 69.455 + 4.3 GGGCCA g GGCTCA 
 
4 2 
Chr17: 17670324 85.537 + 3.8 GGGCCA g AGTGGA + 4 4 
Chr17: 17693258 108.471 + 3.4 AAGCCA c AGGCCA 
 
4 1 
Chr17: 17583572 -1.215 + 3 GGGTCA t ATCCCA 
 
4 4 
Chr17: 17635636 50.849 + 3 AGGCCA c AGGCCT 
 
4 1 
Chr17: 17669804 85.017 + 2.8 AGGCCA g AGACCC + 4 2 
Chr17: 17645391 60.604 + 2.7 AGACCA t AATTCC + 4 4 
Chr17: 17645471 60.684 + 2.4 GAGTCA a GGGGCA + 5 2 
Chr17: 17635502 50.715 + 2.2 GGTTCA a GGCCCA 
 
5 2 
Chr17: 17637686 52.899 + 2.2 AGGTCA a GGCTGC 
 
4 4 
Chr17: 17689768 104.981 + 2.2 AAGTCA a GTTTGA 
 
4 4 
Chr17: 17600476 15.689 + 2.1 AAATCA c AGTTGC + 4 4 
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Chr17: 17609765 24.978 + 1.9 GGGCCA a GGATCC 
 
5 3 
Chr17: 17632951 48.164 + 1.9 AGGTCA a GTTTGT + 4 5 
Chr17: 17640778 55.991 + 1.9 AGGCCA g AGCTGC 
 
4 4 
Chr17: 17642820 58.033 + 1.9 GGGTCA g GGAGCC + 5 3 
Chr17: 17641668 56.881 + 1.7 AGTTCC t GGTTCA + 3 2 
Chr17: 17630590 45.803 + 1.6 AAGCCA g AGCCCA + 4 2 
Chr17: 17611803 27.016 + 1.5 GATTCA a AGTCCT 
 
5 4 
Chr17: 17617296 32.509 + 1.5 GGACCA g AGATCC + 5 3 
Chr17: 17618940 34.153 + 1.4 AATTCA g ATAGCA 
 
5 3 
Chr17: 17643344 58.557 + 1.4 GAATCA c AGGCCA + 5 4 
Chr17: 17611177 26.39 + 1.2 GGATCA t AGGTGT 
 
5 4 
Chr17: 17660651 75.864 + 1 AGATCA g GAGGCA 
 
5 4 
Chr17: 17674809 90.022 + 1 GGGACA g AGTGCA 
 
3 3 
Chr17: 17664898 80.111 - 8.8 TGATCC c TGAACT + 3 2 
Chr17: 17607888 23.101 - 6.1 AGCTCT g TGACCT 
 
3 3 
Chr17: 17664791 80.004 - 5.6 TGGATC c TGACCT + 3 4 
Chr17: 17687848 103.061 - 5.3 GGAGAT t TGACCT + 3 3 
Chr17: 17581302 -3.485 - 5.2 GGAGTT c TGACCT 
 
3 3 
Chr17: 17654927 70.14 - 4.9 TGCACC g TGGCCC 
 
4 2 
Chr17: 17620994 36.207 - 4.3 GGCCCT c TGAACC 
 
5 4 
Chr17: 17670381 85.594 - 4.3 TGAGCC c TGGCCC + 4 2 
Chr17: 17675827 91.04 - 4 TCCACT g TGGCCC 
 
4 4 
Chr17: 17582203 -2.584 - 3.4 TGAGCT a TGGCTC 
 
4 4 
Chr17: 17689367 104.58 - 3.3 GGCACC c TGGCCT 
 
4 4 
Chr17: 17580217 -4.57 - 3.1 TGAACT c TGGGCT 
 
2 2 
Chr17: 17688562 103.775 - 3 TGCATC c TGGCCT 
 
4 4 
Chr17: 17600347 15.56 - 2.9 TGCCCC t TGGCCC + 5 1 
Chr17: 17686756 101.969 - 2.8 TGAAAT t TTACCT + 2 3 
Chr17: 17590634 5.847 - 2.7 TCCTCT c TGGCCT 
 
4 3 
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Chr17: 17646940 62.153 - 2.6 TGCCTC c TGACCC 
 
5 2 
Chr17: 17657179 72.392 - 2.6 GGAACT g TGGATC 
 
5 4 
Chr17: 17590693 5.906 - 2.5 TGGTCT g TGGACC 
 
5 2 
Chr17: 17654700 69.913 - 2.5 AGAACA g TGACCT 
 
2 3 
Chr17: 17622816 38.029 - 2.4 TGAGCT c TGACCA 
 
2 2 
Chr17: 17662514 77.727 - 2.4 TGACCT c AGACCC + 3 2 
Chr17: 17580925 -3.862 - 2.2 TGAGCC t TGATTT 
 
4 3 
Chr17: 17602158 17.371 - 2.2 TCAGCC a TGATCT + 4 3 
Chr17: 17654082 69.295 - 2.2 TCACCC c TGACTC 
 
7 2 
Chr17: 17665427 80.64 - 2.1 TGGACT c TGCCCT + 2 2 
Chr17: 17692355 107.568 - 2.1 AGGACC c TGGCCT 
 
4 3 
Chr17: 17617240 32.453 - 2 GCGTCT c TGACCT + 4 4 
Chr17: 17690495 105.708 - 1.8 TCCCAT c TGACCC 
 
5 4 
Chr17: 17692143 107.356 - 1.8 GCAGCT c TGGCCT 
 
4 4 
Chr17: 17657095 72.308 - 1.6 ACACAT t TGAACT 
 
5 4 
Chr17: 17623815 39.028 - 1.5 GGCACC a TGATCC 
 
5 3 
Chr17: 17611933 27.146 - 1 TGCATC t TGACTC   5 2 
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